1
|
Prieto-Díaz R, Fojo-Carballo H, Majellaro M, Tandarić T, Azuaje J, Brea J, Loza MI, Barbazán J, Salort G, Chotalia M, Rodríguez-Pampín I, Mallo-Abreu A, Rita Paleo M, García-Mera X, Ciruela F, Gutiérrez-de-Terán H, Sotelo E. Exploring Biginelli-based scaffolds as A 2B adenosine receptor antagonists: Unveiling novel structure-activity relationship trends, lead compounds, and potent colorectal anticancer agents. Biomed Pharmacother 2024; 173:116345. [PMID: 38442670 DOI: 10.1016/j.biopha.2024.116345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Revised: 02/19/2024] [Accepted: 02/23/2024] [Indexed: 03/07/2024] Open
Abstract
Antagonists of the A2B adenosine receptor have recently emerged as targeted anticancer agents and immune checkpoint inhibitors within the realm of cancer immunotherapy. This study presents a comprehensive evaluation of novel Biginelli-assembled pyrimidine chemotypes, including mono-, bi-, and tricyclic derivatives, as A2BAR antagonists. We conducted a comprehensive examination of the adenosinergic profile (both binding and functional) of a large compound library consisting of 168 compounds. This approach unveiled original lead compounds and enabled the identification of novel structure-activity relationship (SAR) trends, which were supported by extensive computational studies, including quantum mechanical calculations and free energy perturbation (FEP) analysis. In total, 25 molecules showed attractive affinity (Ki < 100 nM) and outstanding selectivity for A2BAR. From these, five molecules corresponding to the new benzothiazole scaffold were below the Ki < 10 nM threshold, in addition to a novel dual A2A/A2B antagonist. The most potent compounds, and the dual antagonist, showed enantiospecific recognition in the A2BAR. Two A2BAR selective antagonists and the dual A2AAR/A2BAR antagonist reported in this study were assessed for their impact on colorectal cancer cell lines. The results revealed a significant and dose-dependent reduction in cell proliferation. Notably, the A2BAR antagonists exhibited remarkable specificity, as they did not impede the proliferation of non-tumoral cell lines. These findings support the efficacy and potential that A2BAR antagonists as valuable candidates for cancer therapy, but also that they can effectively complement strategies involving A2AAR antagonism in the context of immune checkpoint inhibition.
Collapse
Affiliation(s)
- Rubén Prieto-Díaz
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Hugo Fojo-Carballo
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Maria Majellaro
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain.
| | - Tana Tandarić
- Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Biomedical Centre, Uppsala 75124, Sweden
| | - Jhonny Azuaje
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - José Brea
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CiMUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain.
| | - María I Loza
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CiMUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Jorge Barbazán
- Grupo de Oncología Médica Traslacional (ONCOMET), Instituto de Investigación Sanitaria, Santiago de Compostela (IDIS), Hospital Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela 15706, Spain.
| | - Glòria Salort
- Unidad de Farmacología, Departamento de Patología y Terapéutica Experimental, Facultad de Medicina y Ciencias de la Salud, Instituto de Neurociencia, Universitat de Barcelona, L'Hospitalet de Llobregat 08907, Spain; Neuropharmacology and Pain Group, Neuroscience Program, Institut d'Investigació Biomèdica de Bellvitge, IDIBELL, L'Hospitalet de Llobregat 08907, Spain; Laboratorio de Neurofarmacología, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Institut d'investigació Sanitària Illes Balears (IdISBa), University of the Balearic Islands, Palma de Mallorca 07122, Spain
| | - Meera Chotalia
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Iván Rodríguez-Pampín
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Ana Mallo-Abreu
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - M Rita Paleo
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Xerardo García-Mera
- Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Francisco Ciruela
- Unidad de Farmacología, Departamento de Patología y Terapéutica Experimental, Facultad de Medicina y Ciencias de la Salud, Instituto de Neurociencia, Universitat de Barcelona, L'Hospitalet de Llobregat 08907, Spain; Neuropharmacology and Pain Group, Neuroscience Program, Institut d'Investigació Biomèdica de Bellvitge, IDIBELL, L'Hospitalet de Llobregat 08907, Spain
| | - Hugo Gutiérrez-de-Terán
- Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Biomedical Centre, Uppsala 75124, Sweden.
| | - Eddy Sotelo
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain.
| |
Collapse
|
2
|
Pereira-Silva M, Miranda-Pastoriza D, Diaz-Gomez L, Sotelo E, Paiva-Santos AC, Veiga F, Concheiro A, Alvarez-Lorenzo C. Gemcitabine-Vitamin E Prodrug-Loaded Micelles for Pancreatic Cancer Therapy. Pharmaceutics 2024; 16:95. [PMID: 38258105 PMCID: PMC10819901 DOI: 10.3390/pharmaceutics16010095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Revised: 01/03/2024] [Accepted: 01/04/2024] [Indexed: 01/24/2024] Open
Abstract
Pancreatic cancer (PC) is an aggressive cancer subtype presenting unmet clinical challenges. Conventional chemotherapy, which includes antimetabolite gemcitabine (GEM), is seriously undermined by a short half-life, its lack of targeting ability, and systemic toxicity. GEM incorporation in self-assembled nanosystems is still underexplored due to GEM's hydrophilicity which hinders efficient encapsulation. We hypothesized that vitamin E succinate-GEM prodrug (VES-GEM conjugate) combines hydrophobicity and multifunctionalities that can facilitate the development of Pluronic® F68 and Pluronic® F127 micelle-based nanocarriers, improving the therapeutic potential of GEM. Pluronic® F68/VES-GEM and Pluronic® F127/VES-GEM micelles covering a wide range of molar ratios were prepared by solvent evaporation applying different purification methods, and characterized regarding size, charge, polydispersity index, morphology, and encapsulation. Moreover, the effect of sonication and ultrasonication and the influence of a co-surfactant were explored together with drug release, stability, blood compatibility, efficacy against tumour cells, and cell uptake. The VES-GEM conjugate-loaded micelles showed acceptable size and high encapsulation efficiency (>95%) following an excipient reduction rationale. Pluronic® F127/VES-GEM micelles evidenced a superior VES-GEM release profile (cumulative release > 50%, pH = 7.4), stability, cell growth inhibition (<50% cell viability for 100 µM VES-GEM), blood compatibility, and extensive cell internalization, and therefore represent a promising approach to leveraging the efficacy and safety of GEM for PC-targeted therapies.
Collapse
Affiliation(s)
- Miguel Pereira-Silva
- Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, 3000-548 Coimbra, Portugal; (M.P.-S.); (A.C.P.-S.); (F.V.)
- REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, 3000-548 Coimbra, Portugal
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain;
| | - Darío Miranda-Pastoriza
- Department of Organic Chemistry, Faculty of Farmacy, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain; (D.M.-P.); (E.S.)
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Luis Diaz-Gomez
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain;
| | - Eddy Sotelo
- Department of Organic Chemistry, Faculty of Farmacy, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain; (D.M.-P.); (E.S.)
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Ana Cláudia Paiva-Santos
- Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, 3000-548 Coimbra, Portugal; (M.P.-S.); (A.C.P.-S.); (F.V.)
- REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, 3000-548 Coimbra, Portugal
| | - Francisco Veiga
- Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, 3000-548 Coimbra, Portugal; (M.P.-S.); (A.C.P.-S.); (F.V.)
- REQUIMTE/LAQV, Group of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, 3000-548 Coimbra, Portugal
| | - Angel Concheiro
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain;
| | - Carmen Alvarez-Lorenzo
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain;
| |
Collapse
|
3
|
Navarro G, Sotelo E, Raïch I, Loza MI, Brea J, Majellaro M. A Robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery. Molecules 2023; 28:8107. [PMID: 38138600 PMCID: PMC10745346 DOI: 10.3390/molecules28248107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Revised: 12/07/2023] [Accepted: 12/08/2023] [Indexed: 12/24/2023] Open
Abstract
The identification of new modulators for Cannabinoid Receptors (CBRs) has garnered significant attention in drug discovery over recent years, owing to their manifold pathophysiological implications. In the context of hit identification, the availability of robust and sensitive high-throughput screening assays is essential to enhance the likelihood of success. In this study, we present the development and validation of a Tag-lite® binding assay designed for screening hCB1/hCB2 binding, employing a dual fluorescent ligand, CELT-335. Representative ligands for CBRs, exhibiting diverse affinity and functional profiles, were utilized as reference compounds to validate the robustness and efficiency of the newly developed Tag-lite® binding assay protocol. The homogeneous format, coupled with the sensitivity and optimal performance of the fluorescent ligand CELT-335, establishes this assay as a viable and reliable method for screening in hit and lead identification campaigns.
Collapse
Affiliation(s)
- Gemma Navarro
- Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Science, University of Barcelona, 08028 Barcelona, Spain
- Institute of Neuroscience of the University of Barcelona, 08035 Barcelona, Spain
| | - Eddy Sotelo
- Department of Organic Chemistry, Center for Research in Biological Chemistry and Molecular Materials (CiQUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain;
| | - Iu Raïch
- Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Science, University of Barcelona, 08028 Barcelona, Spain
- Institute of Neuroscience of the University of Barcelona, 08035 Barcelona, Spain
| | - María Isabel Loza
- Research Center in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain;
| | - Jose Brea
- Research Center in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain;
| | - Maria Majellaro
- Celtarys Research SL, Avda. Mestre Mateo, 2, 15706 Santiago de Compostela, Spain
| |
Collapse
|
4
|
Gioé-Gallo C, Ortigueira S, Brea J, Raïch I, Azuaje J, Paleo MR, Majellaro M, Loza MI, Salas CO, García-Mera X, Navarro G, Sotelo E. Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs. Biomed Pharmacother 2023; 164:114934. [PMID: 37236027 DOI: 10.1016/j.biopha.2023.114934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2022] [Revised: 04/01/2023] [Accepted: 05/22/2023] [Indexed: 05/28/2023] Open
Abstract
Synthetic cannabinoid receptor agonists (SCRAs) constitute the largest and most defiant group of abuse designer drugs. These new psychoactive substances (NPS), developed as unregulated alternatives to cannabis, have potent cannabimimetic effects and their use is usually associated with episodes of psychosis, seizures, dependence, organ toxicity and death. Due to their ever-changing structure, very limited or nil structural, pharmacological, and toxicological information is available to the scientific community and the law enforcement offices. Here we report the synthesis and pharmacological evaluation (binding and functional) of the largest and most diverse collection of enantiopure SCRAs published to date. Our results revealed novel SCRAs that could be (or may currently be) used as illegal psychoactive substances. We also report, for the first time, the cannabimimetic data of 32 novel SCRAs containing an (R) configuration at the stereogenic center. The systematic pharmacological profiling of the library enabled the identification of emerging Structure-Activity Relationship (SAR) and Structure-Selectivity Relationship (SSR) trends, the detection of ligands exhibiting incipient cannabinoid receptor type 2 (CB2R) subtype selectivity and highlights the significant neurotoxicity of representative SCRAs on mouse primary neuronal cells. Several of the new emerging SCRAs are currently expected to have a rather limited potential for harm, as the evaluation of their pharmacological profiles revealed lower potencies and/or efficacies. Conceived as a resource to foster collaborative investigation of the physiological effects of SCRAs, the library obtained can contribute to addressing the challenge posed by recreational designer drugs.
Collapse
Affiliation(s)
- Claudia Gioé-Gallo
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Sandra Ortigueira
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - José Brea
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CiMUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain.
| | - Iu Raïch
- Department of Biochemistry and Physiology, School of Pharmacy and Food Science, Universitat de Barcelona, Barcelona 08028, Spain; Institute of Neurosciences (NeuroUB), Campus Mundet, University of Barcelona, Barcelona 08035, Spain
| | - Jhonny Azuaje
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - M Rita Paleo
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Maria Majellaro
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - María Isabel Loza
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CiMUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Cristian O Salas
- Department of Organic Chemistry, Faculty of Chemistry and Pharmacy, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4860, Macul, Santiago 7820436, Chile
| | - Xerardo García-Mera
- Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Gemma Navarro
- Department of Biochemistry and Physiology, School of Pharmacy and Food Science, Universitat de Barcelona, Barcelona 08028, Spain; Institute of Neurosciences (NeuroUB), Campus Mundet, University of Barcelona, Barcelona 08035, Spain.
| | - Eddy Sotelo
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain; Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain.
| |
Collapse
|
5
|
Jecmenova K, Kotulova J, Gurska S, Majellaro M, Hajduch M, Sotelo E, Gioe-Gallo C, Dzubak P. Abstract 350: Study of A3 adenosine receptor interactions and identification of novel ant-/agonist using a specific fluorescent probe. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Introduction: Adenosine receptors belong to G protein-coupled receptors (GPCRs). There are four types of adenosine receptors (A1, A2A, A2B, and A3). These receptors play roles in several pathological conditions. It has been proven that the A3 adenosine receptor (A3AR) is expressed at high densities in various tumor cells. Activation of this receptor leads, in some cases, to tumor growth and cell proliferation and, in other cases, to activation of apoptotic pathways and mediation of antiproliferative effects. Therefore A3AR is a promising therapeutic target in anticancer therapy. Here we introduce the microscopic technique for A3AR visualization and functional studies using a novel A3AR-specific fluorescent probe. Our method could be used in living cells and competitive binding assays to identify and validate novel A3AR agonists and antagonists. Material and methods: The reporter cell line overexpressing A3AR was treated by the A3AR-specific fluorescent probe (fluorescently labeled A3AR antagonist - CELT-228; Celtarys, Spain), the fluorescent images were taken by spinning disc confocal microscopy (Yokogawa CV8000) at different timepoints and concentrations. Then the localization and intensity of the signal were analyzed by Columbus HCA software. The competitive assay based on the CELT-228 fluorescent probe was developed to study interactions of the potential A3AR agonists or antagonists and used for the High Content Screening of newly synthesized nucleoside-based compounds. The competition assay was used to test the interaction of newly identified A3AR ant-/agonists on cancer cell lines derived from tumors of various histogenetic origins with A3AR expression. The results were correlated with cytotoxicity and molecular pathway alterations induced by the studied compounds. Results: The fluorescent signal of the bound probe was localized on the cell membrane of the reporter cell line and the majority of the cancer cell lines. Interestingly in some cell lines, such as MIA PaCa-2, the signal was also observed in the cytoplasm, which will be further studied. Our data from competition assays indicated that the newly synthesized potential anticancer compound binds to the same (orthosteric) binding site on the A3 receptor and competes for it with the fluorescent-labeled probe. Conclusions: We introduced the technique suitable for observing A3R expression, small molecule competition monitoring, and confirmation of binding to A3AR of novel compounds even in native conditions. This work was supported by European Union - Programme EXCELES, ID Project No. LX22NPO5102, the Czech Ministry of Education, Youth and Sports (CZ-OPENSCREEN - LM2018130, EATRIS-CZ - LM2018133), and by the internal grant of Palacky University Olomouc (IGA_LF_2022_033) and European Regional Development Fund - Project ENOCH (No. CZ.02.1.01/0.0/0.0/16_019/0000868).
Citation Format: Katerina Jecmenova, Jana Kotulova, Sona Gurska, Maria Majellaro, Marian Hajduch, Eddy Sotelo, Claudia Gioe-Gallo, Petr Dzubak. Study of A3 adenosine receptor interactions and identification of novel ant-/agonist using a specific fluorescent probe [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 350.
Collapse
Affiliation(s)
| | - Jana Kotulova
- 1Palacky University in Olomouc, Olomouc, Czech Republic
| | - Sona Gurska
- 1Palacky University in Olomouc, Olomouc, Czech Republic
| | | | | | - Eddy Sotelo
- 3Centro Singular de Investigacion en Quimica Bioloxica e Materiais Moíleculares (CIQUS) and Departmento de Quimica Organica, Santiago de Compostela, Spain
| | - Claudia Gioe-Gallo
- 4Centro Singular de Investigacion en Quimica Bioloxica e Materiais Moíleculares (CIQUS) and Departmento de Quimica Organica, Santiago de Compostela, Spain, Santiago de Compostela, Spain
| | - Petr Dzubak
- 1Palacky University in Olomouc, Olomouc, Czech Republic
| |
Collapse
|
6
|
Graziano G, Stefanachi A, Contino M, Prieto-Díaz R, Ligresti A, Kumar P, Scilimati A, Sotelo E, Leonetti F. Multicomponent Reaction-Assisted Drug Discovery: A Time- and Cost-Effective Green Approach Speeding Up Identification and Optimization of Anticancer Drugs. Int J Mol Sci 2023; 24:ijms24076581. [PMID: 37047554 PMCID: PMC10095429 DOI: 10.3390/ijms24076581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Revised: 03/28/2023] [Accepted: 03/29/2023] [Indexed: 04/05/2023] Open
Abstract
Multicomponent reactions (MCRs) have emerged as a powerful strategy in synthetic organic chemistry due to their widespread applications in drug discovery and development. MCRs are flexible transformations in which three or more substrates react to form structurally complex products with high atomic efficiency. They are being increasingly appreciated as a highly exploratory and evolutionary tool by the medicinal chemistry community, opening the door to more sustainable, cost-effective and rapid synthesis of biologically active molecules. In recent years, MCR-based synthetic strategies have found extensive application in the field of drug discovery, and several anticancer drugs have been synthesized through MCRs. In this review, we present an overview of representative and recent literature examples documenting different approaches and applications of MCRs in the development of new anticancer drugs.
Collapse
Affiliation(s)
- Giovanni Graziano
- Department of Pharmacy—Pharmaceutical Sciences, University of Bari “Aldo Moro”, 70125 Bari, Italy
- Center for Research in Biological Chemistry and Molecular Materials (CiQUS), Department of Organic Chemistry, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Angela Stefanachi
- Department of Pharmacy—Pharmaceutical Sciences, University of Bari “Aldo Moro”, 70125 Bari, Italy
| | - Marialessandra Contino
- Department of Pharmacy—Pharmaceutical Sciences, University of Bari “Aldo Moro”, 70125 Bari, Italy
| | - Rubén Prieto-Díaz
- Center for Research in Biological Chemistry and Molecular Materials (CiQUS), Department of Organic Chemistry, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Alessia Ligresti
- Institute of Biomolecular Chemistry, National Research Council of Italy, 80078 Pozzuoli, Italy
| | - Poulami Kumar
- Institute of Biomolecular Chemistry, National Research Council of Italy, 80078 Pozzuoli, Italy
| | - Antonio Scilimati
- Department of Pharmacy—Pharmaceutical Sciences, University of Bari “Aldo Moro”, 70125 Bari, Italy
| | - Eddy Sotelo
- Center for Research in Biological Chemistry and Molecular Materials (CiQUS), Department of Organic Chemistry, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Francesco Leonetti
- Department of Pharmacy—Pharmaceutical Sciences, University of Bari “Aldo Moro”, 70125 Bari, Italy
| |
Collapse
|
7
|
Abatematteo FS, Majellaro M, Montsch B, Prieto-Díaz R, Niso M, Contino M, Stefanachi A, Riganti C, Mangiatordi GF, Delre P, Heffeter P, Sotelo E, Abate C. Development of Fluorescent 4-[4-(3 H-Spiro[isobenzofuran-1,4'-piperidin]-1'-yl)butyl]indolyl Derivatives as High-Affinity Probes to Enable the Study of σ Receptors via Fluorescence-Based Techniques. J Med Chem 2023; 66:3798-3817. [PMID: 36919956 PMCID: PMC10041534 DOI: 10.1021/acs.jmedchem.2c01227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/16/2023]
Abstract
Sigma (σ) receptor subtypes, σ1 and σ2, are targets of wide pharmaceutical interest. The σ2 receptor holds promise for the development of diagnostics and therapeutics against cancer and Alzheimer's disease. Nevertheless, little is known about the mechanisms activated by the σ2 receptor. To contribute to the exploitation of its therapeutic potential, we developed novel specific fluorescent ligands. Indole derivatives bearing the N-butyl-3H-spiro[isobenzofuran-1,4'-piperidine] portion were functionalized with fluorescent tags. Nanomolar-affinity fluorescent σ ligands, spanning from green to red to near-infrared emission, were obtained. Compounds 19 (σ pan affinity) and 29 (σ2 selective), which displayed the best compromise between pharmacodynamic and photophysical properties, were investigated in flow cytometry, confocal, and live cell microscopy, demonstrating their specificity for the σ2 receptor. To the best of our knowledge, these are the first red-emitting fluorescent σ2 ligands, validated as powerful tools for the study of σ2 receptors via fluorescence-based techniques.
Collapse
Affiliation(s)
| | - Maria Majellaro
- Centro Singular Investigación Quimica Biologica e Materiales Moleculares (CIQUS), Departamento de Quimica Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Bianca Montsch
- Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria
| | - Rubén Prieto-Díaz
- Centro Singular Investigación Quimica Biologica e Materiales Moleculares (CIQUS), Departamento de Quimica Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Mauro Niso
- Dipartimento di Farmacia-Scienze del Farmaco, Via Orabona, 4, 79125 Bari, Italy
| | | | - Angela Stefanachi
- Dipartimento di Farmacia-Scienze del Farmaco, Via Orabona, 4, 79125 Bari, Italy
| | - Chiara Riganti
- Department of Oncology, University of Torino, via Santena 5/bis, 10126 Torino, Italy
| | | | - Pietro Delre
- Consiglio Nazionale delle Ricerche (CNR), Istituto di Cristallografia, Via Amendola, 70126 Bari, Italy
| | - Petra Heffeter
- Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria
| | - Eddy Sotelo
- Centro Singular Investigación Quimica Biologica e Materiales Moleculares (CIQUS), Departamento de Quimica Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Carmen Abate
- Dipartimento di Farmacia-Scienze del Farmaco, Via Orabona, 4, 79125 Bari, Italy
- Consiglio Nazionale delle Ricerche (CNR), Istituto di Cristallografia, Via Amendola, 70126 Bari, Italy
| |
Collapse
|
8
|
Tahk MJ, Laasfeld T, Meriste E, Brea J, Loza MI, Majellaro M, Contino M, Sotelo E, Rinken A. Fluorescence based HTS-compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells. Front Mol Biosci 2023; 10:1119157. [PMID: 37006609 PMCID: PMC10062709 DOI: 10.3389/fmolb.2023.1119157] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Accepted: 02/28/2023] [Indexed: 03/18/2023] Open
Abstract
Dopamine receptors are G-protein-coupled receptors that are connected to severe neurological disorders. The development of new ligands targeting these receptors enables gaining a deeper insight into the receptor functioning, including binding mechanisms, kinetics and oligomerization. Novel fluorescent probes allow the development of more efficient, cheaper, reliable and scalable high-throughput screening systems, which speeds up the drug development process. In this study, we used a novel Cy3B labelled commercially available fluorescent ligand CELT-419 for developing dopamine D3 receptor-ligand binding assays with fluorescence polarization and quantitative live cell epifluorescence microscopy. The fluorescence anisotropy assay using 384-well plates achieved Z’ value of 0.71, which is suitable for high-throughput screening of ligand binding. The assay can also be used to determine the kinetics of both the fluorescent ligand as well as some reference unlabeled ligands. Furthermore, CELT-419 was also used with live HEK293-D3R cells in epifluorescence microscopy imaging for deep-learning-based ligand binding quantification. This makes CELT-419 quite a universal fluorescence probe which has the potential to be also used in more advanced microscopy techniques resulting in more comparable studies.
Collapse
Affiliation(s)
| | - Tõnis Laasfeld
- Institute of Chemistry, University of Tartu, Tartu, Estonia
- Department of Computer Science, University of Tartu, Tartu, Estonia
| | - Elo Meriste
- Institute of Chemistry, University of Tartu, Tartu, Estonia
| | - Jose Brea
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CiMUS), Universidade de Santiago de Compostela, Santiago, Spain
| | - Maria Isabel Loza
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CiMUS), Universidade de Santiago de Compostela, Santiago, Spain
| | - Maria Majellaro
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago, Spain
- Celtarys Research S.L., Santiago, Spain
| | - Marialessandra Contino
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Bari, Italy
| | - Eddy Sotelo
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago, Spain
| | - Ago Rinken
- Institute of Chemistry, University of Tartu, Tartu, Estonia
- *Correspondence: Ago Rinken,
| |
Collapse
|
9
|
Graziano G, Delre P, Carofiglio F, Brea J, Ligresti A, Kostrzewa M, Riganti C, Gioè-Gallo C, Majellaro M, Nicolotti O, Colabufo NA, Abate C, Loza MI, Sotelo E, Mangiatordi GF, Contino M, Stefanachi A, Leonetti F. N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R). Eur J Med Chem 2023; 248:115109. [PMID: 36657299 DOI: 10.1016/j.ejmech.2023.115109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Revised: 12/28/2022] [Accepted: 01/07/2023] [Indexed: 01/15/2023]
Abstract
Cannabinoid type 2 receptor (CB2R) is a G-protein-coupled receptor that, together with Cannabinoid type 1 receptor (CB1R), endogenous cannabinoids and enzymes responsible for their synthesis and degradation, forms the EndoCannabinoid System (ECS). In the last decade, several studies have shown that CB2R is overexpressed in activated central nervous system (CNS) microglia cells, in disorders based on an inflammatory state, such as neurodegenerative diseases, neuropathic pain, and cancer. For this reason, the anti-inflammatory and immune-modulatory potentials of CB2R ligands are emerging as a novel therapeutic approach. The design of selective ligands is however hampered by the high sequence homology of transmembrane domains of CB1R and CB2R. Based on a recent three-arm pharmacophore hypothesis and latest CB2R crystal structures, we designed, synthesized, and evaluated a series of new N-adamantyl-anthranil amide derivatives as CB2R selective ligands. Interestingly, this new class of compounds displayed a high affinity for human CB2R along with an excellent selectivity respect to CB1R. In this respect, compounds exhibiting the best pharmacodynamic profile in terms of CB2R affinity were also evaluated for the functional behavior and molecular docking simulations provided a sound rationale by highlighting the relevance of the arm 1 substitution to prompt CB2R action. Moreover, the modulation of the pro- and anti-inflammatory cytokines production was also investigated to exert the ability of the best compounds to modulate the inflammatory cascade.
Collapse
Affiliation(s)
- Giovanni Graziano
- Department of Pharmacy-Pharmaceutical Sciences, University of the Studies of Bari "Aldo Moro", Via E.Orabona 4, 70125, Bari, Italy
| | - Pietro Delre
- CNR - Institute of Crystallography, Via Giovanni Amendola, 122/O, 70126, Bari, Italy
| | - Francesca Carofiglio
- Department of Pharmacy-Pharmaceutical Sciences, University of the Studies of Bari "Aldo Moro", Via E.Orabona 4, 70125, Bari, Italy
| | - Josè Brea
- Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, Av. Barcelona, 15782, Santiago de Compostela, Spain; Department of Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Alessia Ligresti
- Institute of Biomolecular Chemistry, National Research Council of Italy, Via Campi Flegrei 34, 80078, Pozzuoli, NA, Italy
| | - Magdalena Kostrzewa
- Institute of Biomolecular Chemistry, National Research Council of Italy, Via Campi Flegrei 34, 80078, Pozzuoli, NA, Italy
| | - Chiara Riganti
- Department of Oncology, University of Turin, Turin, Italy
| | - Claudia Gioè-Gallo
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain
| | - Maria Majellaro
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain
| | - Orazio Nicolotti
- Department of Pharmacy-Pharmaceutical Sciences, University of the Studies of Bari "Aldo Moro", Via E.Orabona 4, 70125, Bari, Italy
| | - Nicola Antonio Colabufo
- Department of Pharmacy-Pharmaceutical Sciences, University of the Studies of Bari "Aldo Moro", Via E.Orabona 4, 70125, Bari, Italy
| | - Carmen Abate
- Department of Pharmacy-Pharmaceutical Sciences, University of the Studies of Bari "Aldo Moro", Via E.Orabona 4, 70125, Bari, Italy; CNR - Institute of Crystallography, Via Giovanni Amendola, 122/O, 70126, Bari, Italy
| | - Maria Isabel Loza
- Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, Av. Barcelona, 15782, Santiago de Compostela, Spain; Department of Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Eddy Sotelo
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain
| | | | - Marialessandra Contino
- Department of Pharmacy-Pharmaceutical Sciences, University of the Studies of Bari "Aldo Moro", Via E.Orabona 4, 70125, Bari, Italy.
| | - Angela Stefanachi
- Department of Pharmacy-Pharmaceutical Sciences, University of the Studies of Bari "Aldo Moro", Via E.Orabona 4, 70125, Bari, Italy.
| | - Francesco Leonetti
- Department of Pharmacy-Pharmaceutical Sciences, University of the Studies of Bari "Aldo Moro", Via E.Orabona 4, 70125, Bari, Italy
| |
Collapse
|
10
|
Intranuovo F, Brunetti L, DelRe P, Mangiatordi GF, Stefanachi A, Laghezza A, Niso M, Leonetti F, Loiodice F, Ligresti A, Kostrzewa M, Brea J, Loza MI, Sotelo E, Saviano M, Colabufo NA, Riganti C, Abate C, Contino M. Development of N-(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase. J Med Chem 2023; 66:235-250. [PMID: 36542836 DOI: 10.1021/acs.jmedchem.2c01084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Cannabinoid type 2 receptor (CB2R), belonging to the endocannabinoid system, is overexpressed in pathologies characterized by inflammation, and its activation counteracts inflammatory states. Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of the main endocannabinoid anandamide; thus, the simultaneous CB2R activation and FAAH inhibition may be a synergistic anti-inflammatory strategy. Encouraged by principal component analysis (PCA) data identifying a wide chemical space shared by CB2R and FAAH ligands, we designed a small library of adamantyl-benzamides, as potential dual agents, CB2R agonists, and FAAH inhibitors. The new compounds were tested for their CB2R affinity/selectivity and CB2R and FAAH activity. Derivatives 13, 26, and 27, displaying the best pharmacodynamic profile as CB2R full agonists and FAAH inhibitors, decreased pro-inflammatory and increased anti-inflammatory cytokines production. Molecular docking simulations complemented the experimental findings by providing a molecular rationale behind the observed activities. These multitarget ligands constitute promising anti-inflammatory agents.
Collapse
Affiliation(s)
- Francesca Intranuovo
- Dipartimento di Farmacia-Scienze Del Farmaco, Università Degli Studi di Bari ALDO MORO, Via Orabona 4, Bari 70125, Italy
| | - Leonardo Brunetti
- Dipartimento di Farmacia-Scienze Del Farmaco, Università Degli Studi di Bari ALDO MORO, Via Orabona 4, Bari 70125, Italy
| | - Pietro DelRe
- Institute of Crystallography, National Research Council of Italy, Via Amendola, 122/o, Bari 70126, Italy
| | | | - Angela Stefanachi
- Dipartimento di Farmacia-Scienze Del Farmaco, Università Degli Studi di Bari ALDO MORO, Via Orabona 4, Bari 70125, Italy
| | - Antonio Laghezza
- Dipartimento di Farmacia-Scienze Del Farmaco, Università Degli Studi di Bari ALDO MORO, Via Orabona 4, Bari 70125, Italy
| | - Mauro Niso
- Dipartimento di Farmacia-Scienze Del Farmaco, Università Degli Studi di Bari ALDO MORO, Via Orabona 4, Bari 70125, Italy
| | - Francesco Leonetti
- Dipartimento di Farmacia-Scienze Del Farmaco, Università Degli Studi di Bari ALDO MORO, Via Orabona 4, Bari 70125, Italy
| | - Fulvio Loiodice
- Dipartimento di Farmacia-Scienze Del Farmaco, Università Degli Studi di Bari ALDO MORO, Via Orabona 4, Bari 70125, Italy
| | - Alessia Ligresti
- Institute of Biomolecular Chemistry, National Research Council of Italy, Via Campi Flegrei 34, Pozzuoli 80078, Italy
| | - Magdalena Kostrzewa
- Institute of Biomolecular Chemistry, National Research Council of Italy, Via Campi Flegrei 34, Pozzuoli 80078, Italy
| | - Jose Brea
- Innopharma Screening Platform, BioFarma Research Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, Santiago de Compostela 15782, Spain.,Department of Pharmacology, Pharmacy and Pharmaceutical Technology. School of Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Maria Isabel Loza
- Innopharma Screening Platform, BioFarma Research Group, Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, Santiago de Compostela 15782, Spain.,Department of Pharmacology, Pharmacy and Pharmaceutical Technology. School of Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Eddy Sotelo
- ComBioMed Research Group, Centro de Química Biológica y Materiales Moleculares (CIQUS), University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Michele Saviano
- Institute of Crystallography, National Research Council of Italy, Via Vivaldi, 43, Caserta 81100, Italy
| | - Nicola Antonio Colabufo
- Dipartimento di Farmacia-Scienze Del Farmaco, Università Degli Studi di Bari ALDO MORO, Via Orabona 4, Bari 70125, Italy
| | - Chiara Riganti
- Dipartimento di Oncologia, Università Degli Studi di Torino, Torino 10126, Italy
| | - Carmen Abate
- Dipartimento di Farmacia-Scienze Del Farmaco, Università Degli Studi di Bari ALDO MORO, Via Orabona 4, Bari 70125, Italy.,Institute of Crystallography, National Research Council of Italy, Via Amendola, 122/o, Bari 70126, Italy
| | - Marialessandra Contino
- Dipartimento di Farmacia-Scienze Del Farmaco, Università Degli Studi di Bari ALDO MORO, Via Orabona 4, Bari 70125, Italy
| |
Collapse
|
11
|
Prieto-Díaz R, González-Gómez M, Fojo-Carballo H, Azuaje J, El Maatougui A, Majellaro M, Loza MI, Brea J, Fernández-Dueñas V, Paleo MR, Díaz-Holguín A, Garcia-Pinel B, Mallo-Abreu A, Estévez JC, Andújar-Arias A, García-Mera X, Gomez-Tourino I, Ciruela F, Salas CO, Gutiérrez-de-Terán H, Sotelo E. Exploring the Effect of Halogenation in a Series of Potent and Selective A 2B Adenosine Receptor Antagonists. J Med Chem 2022; 66:890-912. [PMID: 36517209 PMCID: PMC9841532 DOI: 10.1021/acs.jmedchem.2c01768] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The modulation of the A2B adenosine receptor is a promising strategy in cancer (immuno) therapy, with A2BAR antagonists emerging as immune checkpoint inhibitors. Herein, we report a systematic assessment of the impact of (di- and mono-)halogenation at positions 7 and/or 8 on both A2BAR affinity and pharmacokinetic properties of a collection of A2BAR antagonists and its study with structure-based free energy perturbation simulations. Monohalogenation at position 8 produced potent A2BAR ligands irrespective of the nature of the halogen. In contrast, halogenation at position 7 and dihalogenation produced a halogen-size-dependent decay in affinity. Eight novel A2BAR ligands exhibited remarkable affinity (Ki < 10 nM), exquisite subtype selectivity, and enantioselective recognition, with some eutomers eliciting sub-nanomolar affinity. The pharmacokinetic profile of representative derivatives showed enhanced solubility and microsomal stability. Finally, two compounds showed the capacity of reversing the antiproliferative effect of adenosine in activated primary human peripheral blood mononuclear cells.
Collapse
Affiliation(s)
- Rubén Prieto-Díaz
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782Santiago de
Compostela, Spain,Department
of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782Santiago de Compostela, Spain,Department
of Cell and Molecular Biology, Uppsala University, Biomedical Center, 75124Uppsala, Sweden
| | - Manuel González-Gómez
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782Santiago de
Compostela, Spain,Department
of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782Santiago de Compostela, Spain
| | - Hugo Fojo-Carballo
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782Santiago de
Compostela, Spain,Department
of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782Santiago de Compostela, Spain
| | - Jhonny Azuaje
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782Santiago de
Compostela, Spain,Department
of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782Santiago de Compostela, Spain
| | - Abdelaziz El Maatougui
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782Santiago de
Compostela, Spain,Department
of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782Santiago de Compostela, Spain
| | - Maria Majellaro
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782Santiago de
Compostela, Spain,Department
of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782Santiago de Compostela, Spain
| | - María I. Loza
- Center
for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, 15782Santiago de
Compostela, Spain,Department
of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of
Pharmacy, University of Santiago de Compostela, 15782Santiago de
Compostela, Spain
| | - José Brea
- Center
for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, 15782Santiago de
Compostela, Spain,Department
of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of
Pharmacy, University of Santiago de Compostela, 15782Santiago de
Compostela, Spain,. Tel: +34 881815459. Fax: +34-8818115474
| | - Víctor Fernández-Dueñas
- Pharmacology
Unit, Department of Pathology and Experimental Therapeutics, Faculty
of Medicine and Health Sciences, Institute of Neuroscience, University of Barcelona, 08907L’Hospitalet de Llobregat, Spain,Neuropharmacology
and Pain Group, Neuroscience Program, Institut
d’Investigació Biomèdica de Bellvitge, IDIBELL, 08907L’Hospitalet
de Llobregat, Spain
| | - M. Rita Paleo
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782Santiago de
Compostela, Spain,Department
of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782Santiago de Compostela, Spain
| | - Alejandro Díaz-Holguín
- Department
of Cell and Molecular Biology, Uppsala University, Biomedical Center, 75124Uppsala, Sweden
| | - Beatriz Garcia-Pinel
- Center
for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, 15782Santiago de
Compostela, Spain,Department
of Biochemistry and Molecular Biology, Faculty of Pharmacy, University of Santiago de Compostela, 15782Santiago de
Compostela, Spain
| | - Ana Mallo-Abreu
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782Santiago de
Compostela, Spain,Department
of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782Santiago de Compostela, Spain
| | - Juan C. Estévez
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782Santiago de
Compostela, Spain,Department
of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782Santiago de Compostela, Spain
| | - Antonio Andújar-Arias
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782Santiago de
Compostela, Spain,Department
of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782Santiago de Compostela, Spain
| | - Xerardo García-Mera
- Department
of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782Santiago de Compostela, Spain
| | - Iria Gomez-Tourino
- Center
for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, 15782Santiago de
Compostela, Spain
| | - Francisco Ciruela
- Pharmacology
Unit, Department of Pathology and Experimental Therapeutics, Faculty
of Medicine and Health Sciences, Institute of Neuroscience, University of Barcelona, 08907L’Hospitalet de Llobregat, Spain,Neuropharmacology
and Pain Group, Neuroscience Program, Institut
d’Investigació Biomèdica de Bellvitge, IDIBELL, 08907L’Hospitalet
de Llobregat, Spain
| | - Cristian O. Salas
- Department
of Organic Chemistry, Faculty of Chemistry and Pharmacy, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4860, Macul, Santiago7820436, Chile
| | - Hugo Gutiérrez-de-Terán
- Department
of Cell and Molecular Biology, Uppsala University, Biomedical Center, 75124Uppsala, Sweden,. Tel: +46 18
471 5056. Fax: +46 18 536971
| | - Eddy Sotelo
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782Santiago de
Compostela, Spain,Department
of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782Santiago de Compostela, Spain,. Tel: +34 881815732. Fax: +34-881815704
| |
Collapse
|
12
|
Barbazán J, Majellaro M, Martínez AL, Brea JM, Sotelo E, Abal M. Identification of A2BAR as a potential target in colorectal cancer using novel fluorescent GPCR ligands. Biomed Pharmacother 2022; 153:113408. [DOI: 10.1016/j.biopha.2022.113408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Revised: 06/29/2022] [Accepted: 07/11/2022] [Indexed: 11/26/2022] Open
|
13
|
Tay AHM, Prieto-Díaz R, Neo S, Tong L, Chen X, Carannante V, Önfelt B, Hartman J, Haglund F, Majellaro M, Azuaje J, Garcia-Mera X, Brea JM, Loza MI, Jespers W, Gutierrez-de-Teran H, Sotelo E, Lundqvist A. A 2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models. J Immunother Cancer 2022; 10:e004592. [PMID: 35580926 PMCID: PMC9115112 DOI: 10.1136/jitc-2022-004592] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/26/2022] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Adenosine is a metabolite that suppresses antitumor immune response of T and NK cells via extracellular binding to the two subtypes of adenosine-2 receptors, A2ARs. While blockade of the A2AARs subtype effectively rescues lymphocyte activity, with four A2AAR antagonists currently in anticancer clinical trials, less is known for the therapeutic potential of the other A2BAR blockade within cancer immunotherapy. Recent studies suggest the formation of A2AAR/A2BAR dimers in tissues that coexpress the two receptor subtypes, where the A2BAR plays a dominant role, suggesting it as a promising target for cancer immunotherapy. METHODS We report the synthesis and functional evaluation of five potent A2BAR antagonists and a dual A2AAR/A2BAR antagonist. The compounds were designed using previous pharmacological data assisted by modeling studies. Synthesis was developed using multicomponent approaches. Flow cytometry was used to evaluate the phenotype of T and NK cells on A2BAR antagonist treatment. Functional activity of T and NK cells was tested in patient-derived tumor spheroid models. RESULTS We provide data for six novel small molecules: five A2BAR selective antagonists and a dual A2AAR/A2BAR antagonist. The growth of patient-derived breast cancer spheroids is prevented when treated with A2BAR antagonists. To elucidate if this depends on increased lymphocyte activity, immune cells proliferation, and cytokine production, lymphocyte infiltration was evaluated and compared with the potent A2AAR antagonist AZD-4635. We find that A2BAR antagonists rescue T and NK cell proliferation, IFNγ and perforin production, and increase tumor infiltrating lymphocytes infiltration into tumor spheroids without altering the expression of adhesion molecules. CONCLUSIONS Our results demonstrate that A2BAR is a promising target in immunotherapy, identifying ISAM-R56A as the most potent candidate for A2BAR blockade. Inhibition of A2BAR signaling restores T cell function and proliferation. Furthermore, A2BAR and dual A2AAR/A2BAR antagonists showed similar or better results than A2AAR antagonist AZD-4635 reinforcing the idea of dominant role of the A2BAR in the regulation of the immune system.
Collapse
Affiliation(s)
- Apple Hui Min Tay
- Department of Biological Science, Nanyang Technological University, Singapore
- Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
| | - Rubén Prieto-Díaz
- Center for Research in Biological Chemistry and Molecular Materials, University of Santiago de Compostela, Santiago de Compostela, Galicia, Spain
| | - Shiyong Neo
- Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
- Singapore Immunology Network SIgN, Agency for Science, Technology and Research, Singapore, Republic of Singapore
| | - Le Tong
- Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
| | - Xinsong Chen
- Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
| | - Valentina Carannante
- Department of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
- Department of Applied Physics, Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Björn Önfelt
- Department of Microbiology Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
- Department of Applied Physics, Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Johan Hartman
- Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
- Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden
| | - Felix Haglund
- Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
- Department of Clinical Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden
| | - Maria Majellaro
- Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela, Santiago de Compostela, Galicia, Spain
| | - Jhonny Azuaje
- Center for Research in Biological Chemistry and Molecular Materials, University of Santiago de Compostela, Santiago de Compostela, Galicia, Spain
| | - Xerardo Garcia-Mera
- Center for Research in Biological Chemistry and Molecular Materials, University of Santiago de Compostela, Santiago de Compostela, Galicia, Spain
| | - Jose M Brea
- Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela, Santiago de Compostela, Galicia, Spain
| | - Maria I Loza
- Center for Research in Molecular Medicine and Chronic Diseases, University of Santiago de Compostela, Santiago de Compostela, Galicia, Spain
| | - Willem Jespers
- Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden
| | - Hugo Gutierrez-de-Teran
- Department of Cell and Molecular Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
| | - Eddy Sotelo
- Center for Research in Biological Chemistry and Molecular Materials, University of Santiago de Compostela, Santiago de Compostela, Galicia, Spain
| | - Andreas Lundqvist
- Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
| |
Collapse
|
14
|
Miranda-Pastoriza D, Bernárdez R, Azuaje J, Prieto-Díaz R, Majellaro M, Tamhankar AV, Koenekoop L, González A, Gioé-Gallo C, Mallo-Abreu A, Brea J, Loza MI, García-Rey A, García-Mera X, Gutiérrez-de-Terán H, Sotelo E. Exploring Non-orthosteric Interactions with a Series of Potent and Selective A 3 Antagonists. ACS Med Chem Lett 2022; 13:243-249. [PMID: 35178181 PMCID: PMC8842279 DOI: 10.1021/acsmedchemlett.1c00598] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2021] [Accepted: 01/06/2022] [Indexed: 12/18/2022] Open
Abstract
![]()
A library of potent
and highly A3AR selective pyrimidine-based
compounds was designed to explore non-orthosteric interactions within
this receptor. Starting from a prototypical orthosteric A3AR antagonist (ISVY130), the structure-based design explored functionalized
residues at the exocyclic amide L1 region and aimed to provide additional
interactions outside the A3AR orthosteric site. The novel
ligands were assembled through an efficient and succinct synthetic
approach, resulting in compounds that retain the A3AR potent
and selective profile while improving the solubility of the original
scaffold. The experimentally demonstrated tolerability of the L1 region
to structural functionalization was further assessed by molecular
dynamics simulations, giving hints of the non-orthosteric interactions
explored by these series. The results pave the way to explore newly
functionalized A3AR ligands, including covalent drugs and
molecular probes for diagnostic and delivery purposes.
Collapse
Affiliation(s)
| | | | | | - Rubén Prieto-Díaz
- Department of Cell and Molecular Biology, SciLifeLab, Uppsala University, Uppsala SE-75124, Sweden
| | | | - Ashish V. Tamhankar
- Department of Cell and Molecular Biology, SciLifeLab, Uppsala University, Uppsala SE-75124, Sweden
| | - Lucien Koenekoop
- Department of Cell and Molecular Biology, SciLifeLab, Uppsala University, Uppsala SE-75124, Sweden
| | - Alejandro González
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS). Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | | | | | - José Brea
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS). Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - M. Isabel Loza
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS). Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | | | | | - Hugo Gutiérrez-de-Terán
- Department of Cell and Molecular Biology, SciLifeLab, Uppsala University, Uppsala SE-75124, Sweden
| | | |
Collapse
|
15
|
Val C, Rodríguez-García C, Prieto-Díaz R, Crespo A, Azuaje J, Carbajales C, Majellaro M, Díaz-Holguín A, Brea JM, Loza MI, Gioé-Gallo C, Contino M, Stefanachi A, García-Mera X, Estévez JC, Gutiérrez-de-Terán H, Sotelo E. Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A1 Antagonists. J Med Chem 2022; 65:2091-2106. [PMID: 35068155 PMCID: PMC8842224 DOI: 10.1021/acs.jmedchem.1c01636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
![]()
We herein document a large collection
of 108 2-amino-4,6-disubstituted-pyrimidine
derivatives as potent, structurally simple, and highly selective A1AR ligands. The most attractive ligands were confirmed as
antagonists of the canonical cyclic adenosine monophosphate pathway,
and some pharmacokinetic parameters were preliminarilly evaluated.
The library, built through a reliable and efficient three-component
reaction, comprehensively explored the chemical space allowing the
identification of the most prominent features of the structure–activity
and structure–selectivity relationships around this scaffold.
These included the influence on the selectivity profile of the aromatic
residues at positions R4 and R6 of the pyrimidine
core but most importantly the prominent role to the unprecedented
A1AR selectivity profile exerted by the methyl group introduced
at the exocyclic amino group. The structure–activity relationship
trends on both A1 and A2AARs were conveniently
interpreted with rigorous free energy perturbation simulations, which
started from the receptor-driven docking model that guided the design
of these series.
Collapse
Affiliation(s)
- Cristina Val
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
- Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Carlos Rodríguez-García
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
- Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Rubén Prieto-Díaz
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
- Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
- Department of Cell and Molecular Biology, Uppsala University, Uppsala 75124, Sweden
| | - Abel Crespo
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
- Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Jhonny Azuaje
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
- Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Carlos Carbajales
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
- Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Maria Majellaro
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
- Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | | | - José M. Brea
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CiMUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Maria Isabel Loza
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CiMUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Claudia Gioé-Gallo
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
- Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Marialessandra Contino
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, via Orabona 4, Bari 70125, Italy
| | - Angela Stefanachi
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, via Orabona 4, Bari 70125, Italy
| | - Xerardo García-Mera
- Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Juan C. Estévez
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| | | | - Eddy Sotelo
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
- Departamento de Química Orgánica, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain
| |
Collapse
|
16
|
Jespers W, Heitman LH, IJzerman AP, Sotelo E, van Westen GJP, Åqvist J, Gutiérrez-de-Terán H. Deciphering conformational selectivity in the A2A adenosine G protein-coupled receptor by free energy simulations. PLoS Comput Biol 2021; 17:e1009152. [PMID: 34818333 PMCID: PMC8654218 DOI: 10.1371/journal.pcbi.1009152] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 12/08/2021] [Accepted: 11/11/2021] [Indexed: 12/25/2022] Open
Abstract
Transmembranal G Protein-Coupled Receptors (GPCRs) transduce extracellular chemical signals to the cell, via conformational change from a resting (inactive) to an active (canonically bound to a G-protein) conformation. Receptor activation is normally modulated by extracellular ligand binding, but mutations in the receptor can also shift this equilibrium by stabilizing different conformational states. In this work, we built structure-energetic relationships of receptor activation based on original thermodynamic cycles that represent the conformational equilibrium of the prototypical A2A adenosine receptor (AR). These cycles were solved with efficient free energy perturbation (FEP) protocols, allowing to distinguish the pharmacological profile of different series of A2AAR agonists with different efficacies. The modulatory effects of point mutations on the basal activity of the receptor or on ligand efficacies could also be detected. This methodology can guide GPCR ligand design with tailored pharmacological properties, or allow the identification of mutations that modulate receptor activation with potential clinical implications. The design of new ligands as chemical modulators of G protein-coupled receptors (GPCRs) has benefited considerably during the last years of advances in both the structural and computational biology disciplines. Within the last area, the use of free energy calculation methods has arisen as a computational tool to predict ligand affinities to explain structure-affinity relationships and guide lead optimization campaigns. However, our comprehension of the structural determinants of ligands with different pharmacological profile is scarce, and knowledge of the chemical modifications associated with an agonistic or antagonistic profile would be extremely valuable. We herein report an original implementation of the thermodynamic cycles associated with free energy perturbation (FEP) simulations, to mimic the conformational equilibrium between active and inactive GPCRs, and establish a framework to describe pharmacological profiles as a function of the ligands selectivity for a given receptor conformation. The advantage of this method resides into its simplicity of use, and the only consideration of active and inactive conformations of the receptor, with no simulation of the transitions between them. This model can accurately predict the pharmacological profile of series of full and partial agonists as opposed to antagonists of the A2A adenosine receptor, and moreover, how certain mutations associated with modulation of basal activity can influence this pharmacological profiles, which enables our understanding of such clinically relevant mutations.
Collapse
Affiliation(s)
- Willem Jespers
- Department of Cell and Molecular Biology, Uppsala University, Biomedical Center (BMC), Uppsala, Sweden
- Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden, The Netherlands
- * E-mail: (WJ); (HGT)
| | - Laura H. Heitman
- Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden, The Netherlands
- Oncode Institute, Leiden, Leiden
| | - Adriaan P. IJzerman
- Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden, The Netherlands
| | - Eddy Sotelo
- Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CIQUS), Santiago de Compostela, Spain
- Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, Santiago de Compostela, Spain
| | - Gerard J. P. van Westen
- Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden, The Netherlands
| | - Johan Åqvist
- Department of Cell and Molecular Biology, Uppsala University, Biomedical Center (BMC), Uppsala, Sweden
| | - Hugo Gutiérrez-de-Terán
- Department of Cell and Molecular Biology, Uppsala University, Biomedical Center (BMC), Uppsala, Sweden
- Science for Life Laboratories, BMC, Uppsala, Sweden
- * E-mail: (WJ); (HGT)
| |
Collapse
|
17
|
Raïch I, Rivas-Santisteban R, Lillo A, Lillo J, Reyes-Resina I, Nadal X, Ferreiro-Vera C, de Medina VS, Majellaro M, Sotelo E, Navarro G, Franco R. Similarities and differences upon binding of naturally occurring Δ 9-tetrahydrocannabinol-derivatives to cannabinoid CB 1 and CB 2 receptors. Pharmacol Res 2021; 174:105970. [PMID: 34758399 DOI: 10.1016/j.phrs.2021.105970] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2021] [Revised: 11/01/2021] [Accepted: 11/02/2021] [Indexed: 12/18/2022]
Abstract
We have here assessed, using Δ9-tetrahydrocannabinol (Δ9-THC) for comparison, the effect of Δ9-tetrahydrocannabinolic acid (Δ9-THCA) and of Δ9-tetrahydrocannabivarin (Δ9-THCV) that is mediated by human versions of CB1, CB2, and CB1-CB2 receptor functional units, expressed in a heterologous system. Binding to the CB1 and CB2 receptors was addressed in living cells by means of a homogeneous assay. A biphasic competition curve for the binding to the CB2 receptor, was obtained for Δ9-THCV in cells expressing the two receptors. Signaling studies included cAMP level determination, activation of the mitogen-activated protein kinase pathway and ß-arrestin recruitment were performed. The signaling triggered by Δ9-THCA and Δ9-THCV via individual receptors or receptor heteromers disclosed differential bias, i.e. the bias observed using a given phytocannabinoid depended on the receptor (CB1, CB2 or CB1-CB2) and on the compound used as reference to calculate the bias factor (Δ9-THC, a selective agonist or a non-selective agonist). These results are consistent with different binding modes leading to differential functional selectivity depending on the agonist structure, and the state (monomeric or heteromeric) of the cannabinoid receptor. In addition, on studying Gi-coupling we showed that Δ9-THCV and Δ9-THCA and Δ9-THCV were able to revert the effect of a selective CB2 receptor agonist, but only Δ9-THCV, and not Δ9-THCA, reverted the effect of arachidonyl-2'-chloroethylamide (ACEA 100 nM) a selective agonist of the CB1 receptor. Overall, these results indicate that cannabinoids may have a variety of binding modes that results in qualitatively different effects depending on the signaling pathway that is engaged upon cannabinoid receptor activation.
Collapse
Affiliation(s)
- Iu Raïch
- Department of Biochemistry and Molecular Biomedicine, School of Biology, University of Barcelona, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CiberNed), Spanish National Institute of Health, Carlos iii, 28034 Madrid, Spain
| | - Rafael Rivas-Santisteban
- Department of Biochemistry and Molecular Biomedicine, School of Biology, University of Barcelona, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CiberNed), Spanish National Institute of Health, Carlos iii, 28034 Madrid, Spain
| | - Alejandro Lillo
- Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Science, University of Barcelona, 08028 Barcelona, Spain
| | - Jaume Lillo
- Department of Biochemistry and Molecular Biomedicine, School of Biology, University of Barcelona, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CiberNed), Spanish National Institute of Health, Carlos iii, 28034 Madrid, Spain
| | - Irene Reyes-Resina
- Department of Biochemistry and Molecular Biomedicine, School of Biology, University of Barcelona, 08028 Barcelona, Spain; RG Neuroplasticity, Leibniz Institute for Neurobiology, Magdeburg, Saxony-Anhalt 39118, Germany
| | - Xavier Nadal
- Ethnophytotech Research & Consulting S.L.U., Córdoba, Spain
| | | | | | - Maria Majellaro
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS) Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Eddy Sotelo
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS) Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Gemma Navarro
- Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Science, University of Barcelona, 08028 Barcelona, Spain; Institut de Neurociències de la Universitat de Barcelona, Barcelona, Spain.
| | - Rafael Franco
- Department of Biochemistry and Molecular Biomedicine, School of Biology, University of Barcelona, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CiberNed), Spanish National Institute of Health, Carlos iii, 28034 Madrid, Spain; School of Chemistry. University of Barcelona, Barcelona, Spain.
| |
Collapse
|
18
|
Mallo-Abreu A, Reyes-Resina I, Azuaje J, Franco R, García-Rey A, Majellaro M, Miranda-Pastoriza D, García-Mera X, Jespers W, Gutiérrez-de-Terán H, Navarro G, Sotelo E. Potent and Subtype-Selective Dopamine D 2 Receptor Biased Partial Agonists Discovered via an Ugi-Based Approach. J Med Chem 2021; 64:8710-8726. [PMID: 34110150 PMCID: PMC8552448 DOI: 10.1021/acs.jmedchem.1c00704] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
![]()
Using
a previously unexplored, efficient, and versatile multicomponent
method, we herein report the rapid generation of novel potent and
subtype-selective DRD2 biased partial agonists. This strategy
exemplifies the search for diverse and previously unexplored moieties
for the secondary/allosteric pharmacophore of the common phenyl-piperazine
scaffold. The pharmacological characterization of the new compound
series led to the identification of several ligands with excellent
DRD2 affinity and subtype selectivity and remarkable functional
selectivity for either the cAMP (22a and 24d) or the β-arrestin (27a and 29c)
signaling pathways. These results were further interpreted on the
basis of molecular models of these ligands in complex with the recent
DRD2 crystal structures, highlighting the critical role
of the secondary/allosteric pharmacophore in modulating the functional
selectivity profile.
Collapse
Affiliation(s)
- Ana Mallo-Abreu
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.,Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Irene Reyes-Resina
- Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Science, University of Barcelona, 08028 Barcelona, Spain.,Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain
| | - Jhonny Azuaje
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.,Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Rafael Franco
- Faculty of Chemistry, University of Barcelona, 08028 Barcelona, Spain.,Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain
| | - Aitor García-Rey
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.,Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Maria Majellaro
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.,Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Darío Miranda-Pastoriza
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.,Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Xerardo García-Mera
- Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Willem Jespers
- Department of Cell and Molecular Biology, Uppsala University, Uppsala SE-75124, Sweden
| | | | - Gemma Navarro
- Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Science, University of Barcelona, 08028 Barcelona, Spain.,Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain
| | - Eddy Sotelo
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.,Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| |
Collapse
|
19
|
Azuaje J, Rama A, Mallo-Abreu A, Boado MG, Majellaro M, Tubío CR, Prieto R, García-Mera X, Guitián F, Sotelo E, Gil A. Catalytic performance of a metal-free graphene oxide-Al2O3 composite assembled by 3D printing. Ann Ital Chir 2021. [DOI: 10.1016/j.jeurceramsoc.2020.10.010] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
20
|
Alvarez-Astorga A, García-Azorín D, Hernández M, de la Red H, Sotelo E, Uribe F, Guerrero A. Pain catastrophising in a population of patients with migraine. Neurología (English Edition) 2021. [DOI: 10.1016/j.nrleng.2018.10.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
|
21
|
Alvarez-Astorga A, García-Azorín D, Hernández M, de la Red H, Sotelo E, Uribe F, Guerrero A. Pensamiento catastrófico ante el dolor: presencia en una población de migrañosos. Neurologia 2021; 36:24-28. [DOI: 10.1016/j.nrl.2018.10.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Revised: 10/18/2018] [Accepted: 10/29/2018] [Indexed: 01/03/2023] Open
|
22
|
Majellaro M, Jespers W, Crespo A, Núñez MJ, Novio S, Azuaje J, Prieto-Díaz R, Gioé C, Alispahic B, Brea J, Loza MI, Freire-Garabal M, Garcia-Santiago C, Rodríguez-García C, García-Mera X, Caamaño O, Fernandez-Masaguer C, Sardina JF, Stefanachi A, El Maatougui A, Mallo-Abreu A, Åqvist J, Gutiérrez-de-Terán H, Sotelo E. 3,4-Dihydropyrimidin-2(1 H)-ones as Antagonists of the Human A 2B Adenosine Receptor: Optimization, Structure-Activity Relationship Studies, and Enantiospecific Recognition. J Med Chem 2020; 64:458-480. [PMID: 33372800 DOI: 10.1021/acs.jmedchem.0c01431] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
We present and thoroughly characterize a large collection of 3,4-dihydropyrimidin-2(1H)-ones as A2BAR antagonists, an emerging strategy in cancer (immuno) therapy. Most compounds selectively bind A2BAR, with a number of potent and selective antagonists further confirmed by functional cyclic adenosine monophosphate experiments. The series was analyzed with one of the most exhaustive free energy perturbation studies on a GPCR, obtaining an accurate model of the structure-activity relationship of this chemotype. The stereospecific binding modeled for this scaffold was confirmed by resolving the two most potent ligands [(±)-47, and (±)-38 Ki = 10.20 and 23.6 nM, respectively] into their two enantiomers, isolating the affinity on the corresponding (S)-eutomers (Ki = 6.30 and 11.10 nM, respectively). The assessment of the effect in representative cytochromes (CYP3A4 and CYP2D6) demonstrated insignificant inhibitory activity, while in vitro experiments in three prostate cancer cells demonstrated that this pair of compounds exhibits a pronounced antimetastatic effect.
Collapse
Affiliation(s)
- María Majellaro
- Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.,Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Willem Jespers
- Department of Cell and Molecular Biology, Uppsala University, SE-75124 Uppsala, Sweden
| | - Abel Crespo
- Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.,Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - María J Núñez
- SNL, Departamento de Farmacología, Facultade de Medicina, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Silvia Novio
- SNL, Departamento de Farmacología, Facultade de Medicina, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Jhonny Azuaje
- Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.,Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Rubén Prieto-Díaz
- Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.,Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Claudia Gioé
- Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.,Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Belma Alispahic
- Department of Cell and Molecular Biology, Uppsala University, SE-75124 Uppsala, Sweden
| | - José Brea
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - María I Loza
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Manuel Freire-Garabal
- SNL, Departamento de Farmacología, Facultade de Medicina, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Carlota Garcia-Santiago
- SNL, Departamento de Farmacología, Facultade de Medicina, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Carlos Rodríguez-García
- Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.,Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Xerardo García-Mera
- Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Olga Caamaño
- Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Christian Fernandez-Masaguer
- Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Javier F Sardina
- Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Angela Stefanachi
- Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari ALDO MORO, via Orabona 4, 70125 Bari, Italy
| | - Abdelaziz El Maatougui
- Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.,Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Ana Mallo-Abreu
- Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.,Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Johan Åqvist
- Department of Cell and Molecular Biology, Uppsala University, SE-75124 Uppsala, Sweden
| | | | - Eddy Sotelo
- Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.,Departamento de Química Orgánica, Facultade de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| |
Collapse
|
23
|
Jespers W, Verdon G, Azuaje J, Majellaro M, Keränen H, García‐Mera X, Congreve M, Deflorian F, de Graaf C, Zhukov A, Doré AS, Mason JS, Åqvist J, Cooke RM, Sotelo E, Gutiérrez‐de‐Terán H. X-Ray Crystallography and Free Energy Calculations Reveal the Binding Mechanism of A 2A Adenosine Receptor Antagonists. Angew Chem Int Ed Engl 2020; 59:16536-16543. [PMID: 32542862 PMCID: PMC7540567 DOI: 10.1002/anie.202003788] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Revised: 05/18/2020] [Indexed: 01/04/2023]
Abstract
We present a robust protocol based on iterations of free energy perturbation (FEP) calculations, chemical synthesis, biophysical mapping and X-ray crystallography to reveal the binding mode of an antagonist series to the A2A adenosine receptor (AR). Eight A2A AR binding site mutations from biophysical mapping experiments were initially analyzed with sidechain FEP simulations, performed on alternate binding modes. The results distinctively supported one binding mode, which was subsequently used to design new chromone derivatives. Their affinities for the A2A AR were experimentally determined and investigated through a cycle of ligand-FEP calculations, validating the binding orientation of the different chemical substituents proposed. Subsequent X-ray crystallography of the A2A AR with a low and a high affinity chromone derivative confirmed the predicted binding orientation. The new molecules and structures here reported were driven by free energy calculations, and provide new insights on antagonist binding to the A2A AR, an emerging target in immuno-oncology.
Collapse
Affiliation(s)
- Willem Jespers
- Department of Cell and Molecular BiologyUppsala University, BMC, Biomedical CenterBox 596UppsalaSweden
| | - Grégory Verdon
- Sosei HeptaresSteinmetz Granta Park, Great AbingtonCambridgeCB21 6DGUK
| | - Jhonny Azuaje
- Departament of Organic ChemistryFaculty of FarmacyUniversidade de Santiago de CompostelaSpain
- Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CIQUS)Universidade de Santiago de CompostelaSpain
| | - Maria Majellaro
- Departament of Organic ChemistryFaculty of FarmacyUniversidade de Santiago de CompostelaSpain
- Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CIQUS)Universidade de Santiago de CompostelaSpain
| | - Henrik Keränen
- Department of Cell and Molecular BiologyUppsala University, BMC, Biomedical CenterBox 596UppsalaSweden
- Present address: H. Lundbeck A/SOttiliavej 92500ValbyDenmark
| | - Xerardo García‐Mera
- Departament of Organic ChemistryFaculty of FarmacyUniversidade de Santiago de CompostelaSpain
| | - Miles Congreve
- Sosei HeptaresSteinmetz Granta Park, Great AbingtonCambridgeCB21 6DGUK
| | | | - Chris de Graaf
- Sosei HeptaresSteinmetz Granta Park, Great AbingtonCambridgeCB21 6DGUK
| | - Andrei Zhukov
- Sosei HeptaresSteinmetz Granta Park, Great AbingtonCambridgeCB21 6DGUK
| | - Andrew S. Doré
- Sosei HeptaresSteinmetz Granta Park, Great AbingtonCambridgeCB21 6DGUK
| | - Jonathan S. Mason
- Sosei HeptaresSteinmetz Granta Park, Great AbingtonCambridgeCB21 6DGUK
| | - Johan Åqvist
- Department of Cell and Molecular BiologyUppsala University, BMC, Biomedical CenterBox 596UppsalaSweden
| | - Robert M. Cooke
- Sosei HeptaresSteinmetz Granta Park, Great AbingtonCambridgeCB21 6DGUK
| | - Eddy Sotelo
- Departament of Organic ChemistryFaculty of FarmacyUniversidade de Santiago de CompostelaSpain
- Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CIQUS)Universidade de Santiago de CompostelaSpain
| | - Hugo Gutiérrez‐de‐Terán
- Department of Cell and Molecular BiologyUppsala University, BMC, Biomedical CenterBox 596UppsalaSweden
| |
Collapse
|
24
|
Jespers W, Verdon G, Azuaje J, Majellaro M, Keränen H, García‐Mera X, Congreve M, Deflorian F, Graaf C, Zhukov A, Doré AS, Mason JS, Åqvist J, Cooke RM, Sotelo E, Gutiérrez‐de‐Terán H. X‐Ray Crystallography and Free Energy Calculations Reveal the Binding Mechanism of A
2A
Adenosine Receptor Antagonists. Angew Chem Int Ed Engl 2020. [DOI: 10.1002/ange.202003788] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Willem Jespers
- Department of Cell and Molecular BiologyUppsala University, BMC, Biomedical Center Box 596 Uppsala Sweden
| | - Grégory Verdon
- Sosei Heptares Steinmetz Granta Park, Great Abington Cambridge CB21 6DG UK
| | - Jhonny Azuaje
- Departament of Organic ChemistryFaculty of FarmacyUniversidade de Santiago de Compostela Spain
- Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CIQUS)Universidade de Santiago de Compostela Spain
| | - Maria Majellaro
- Departament of Organic ChemistryFaculty of FarmacyUniversidade de Santiago de Compostela Spain
- Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CIQUS)Universidade de Santiago de Compostela Spain
| | - Henrik Keränen
- Department of Cell and Molecular BiologyUppsala University, BMC, Biomedical Center Box 596 Uppsala Sweden
- Present address: H. Lundbeck A/S Ottiliavej 9 2500 Valby Denmark
| | - Xerardo García‐Mera
- Departament of Organic ChemistryFaculty of FarmacyUniversidade de Santiago de Compostela Spain
| | - Miles Congreve
- Sosei Heptares Steinmetz Granta Park, Great Abington Cambridge CB21 6DG UK
| | | | - Chris Graaf
- Sosei Heptares Steinmetz Granta Park, Great Abington Cambridge CB21 6DG UK
| | - Andrei Zhukov
- Sosei Heptares Steinmetz Granta Park, Great Abington Cambridge CB21 6DG UK
| | - Andrew S. Doré
- Sosei Heptares Steinmetz Granta Park, Great Abington Cambridge CB21 6DG UK
| | - Jonathan S. Mason
- Sosei Heptares Steinmetz Granta Park, Great Abington Cambridge CB21 6DG UK
| | - Johan Åqvist
- Department of Cell and Molecular BiologyUppsala University, BMC, Biomedical Center Box 596 Uppsala Sweden
| | - Robert M. Cooke
- Sosei Heptares Steinmetz Granta Park, Great Abington Cambridge CB21 6DG UK
| | - Eddy Sotelo
- Departament of Organic ChemistryFaculty of FarmacyUniversidade de Santiago de Compostela Spain
- Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CIQUS)Universidade de Santiago de Compostela Spain
| | - Hugo Gutiérrez‐de‐Terán
- Department of Cell and Molecular BiologyUppsala University, BMC, Biomedical Center Box 596 Uppsala Sweden
| |
Collapse
|
25
|
Mallo-Abreu A, Prieto-Díaz R, Jespers W, Azuaje J, Majellaro M, Velando C, García-Mera X, Caamaño O, Brea J, Loza MI, Gutiérrez-de-Terán H, Sotelo E. Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A 2B Adenosine Receptor Antagonists. J Med Chem 2020; 63:7721-7739. [PMID: 32573250 DOI: 10.1021/acs.jmedchem.0c00564] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
A systematic exploration of bioisosteric replacements for furan and thiophene cores in a series of potent A2BAR antagonists has been carried out using the nitrogen-walk approach. A collection of 42 novel alkyl 4-substituted-2-methyl-1,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrimidine-3-carboxylates, which contain 18 different pentagonal heterocyclic frameworks at position 4, was synthesized and evaluated. This study enabled the identification of new ligands that combine remarkable affinity (Ki < 30 nM) and exquisite selectivity. The structure-activity relationship (SAR) trends identified were substantiated by a molecular modeling study, based on a receptor-driven docking model and including a systematic free energy perturbation (FEP) study. Preliminary evaluation of the CYP3A4 and CYP2D6 inhibitory activity in optimized ligands evidenced weak and negligible activity, respectively. The stereospecific interaction between hA2BAR and the eutomer of the most attractive novel antagonist (S)-18g (Ki = 3.66 nM) was validated.
Collapse
Affiliation(s)
| | | | - Willem Jespers
- Department of Cell and Molecular Biology, Uppsala University, Uppsala SE 75124, Sweden
| | | | | | | | | | | | - José Brea
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - María I Loza
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | | | | |
Collapse
|
26
|
Sommer ME, Selent J, Carlsson J, De Graaf C, Gloriam DE, Keseru GM, Kosloff M, Mordalski S, Rizk A, Rosenkilde MM, Sotelo E, Tiemann JKS, Tobin A, Vardjan N, Waldhoer M, Kolb P. The European Research Network on Signal Transduction (ERNEST): Toward a Multidimensional Holistic Understanding of G Protein-Coupled Receptor Signaling. ACS Pharmacol Transl Sci 2020; 3:361-370. [PMID: 32296774 DOI: 10.1021/acsptsci.0c00024] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2020] [Indexed: 12/14/2022]
Abstract
G protein-coupled receptors (GPCRs) are intensively studied due to their therapeutic potential as drug targets. Members of this large family of transmembrane receptor proteins mediate signal transduction in diverse cell types and play key roles in human physiology and health. In 2013 the research consortium GLISTEN (COST Action CM1207) was founded with the goal of harnessing the substantial growth in knowledge of GPCR structure and dynamics to push forward the development of molecular modulators of GPCR function. The success of GLISTEN, coupled with new findings and paradigm shifts in the field, led in 2019 to the creation of a related consortium called ERNEST (COST Action CA18133). ERNEST broadens focus to entire signaling cascades, based on emerging ideas of how complexity and specificity in signal transduction are not determined by receptor-ligand interactions alone. A holistic approach that unites the diverse data and perspectives of the research community into a single multidimensional map holds great promise for improved drug design and therapeutic targeting.
Collapse
Affiliation(s)
- Martha E Sommer
- Institute of Medical Physics and Biophysics, Charité-Universitätsmedizin Berlin, Berlin, 10117, Germany.,Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, 13125, Germany
| | - Jana Selent
- Research Programme on Biomedical Informatics (GRIB), Hospital del Mar Medical Research Institute (IMIM) - Pompeu Fabra University (UPF), Barcelona, 08003, Spain
| | - Jens Carlsson
- Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University, Uppsala, 752 36, Sweden
| | | | - David E Gloriam
- Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, 1017, Denmark
| | - Gyorgy M Keseru
- Medicinal Chemistry Research Group, Research Center for Natural Sciences (RCNS), Budapest, H-1117, Hungary
| | - Mickey Kosloff
- Department of Human Biology, University of Haifa, Haifa, 3498838, Israel
| | - Stefan Mordalski
- Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, 1017, Denmark.,Department of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, 31-343, Poland
| | - Aurelien Rizk
- InterAx Biotech AG, PARK innovAARE, Villigen, 5234, Switzerland
| | - Mette M Rosenkilde
- Laboratory for Molecular Pharmacology, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DK 2200, Denmark
| | - Eddy Sotelo
- Centro Singular de Investigación en Química Biolóxica y Materiais Moleculares (CIQUS) and Facultade de Farmacia. Universidade de Santiago de Compostela, Santiago de compostela, 15782, Spain
| | - Johanna K S Tiemann
- Institute for Medical Physics and Biophysics, Leipzig University, Leipzig, 04109, Germany.,Linderstrøm-Lang Centre for Protein Science, Department of Biology, University of Copenhagen, Kobenhavn, 2200, Denmark
| | - Andrew Tobin
- The Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, U.K
| | - Nina Vardjan
- Laboratory of Neuroendocrinology-Molecular Cell Physiology, Institute of Pathophysiology, Faculty of Medicine, University of Ljubljana, Ljubljana, 1000, Slovenia.,Laboratory of Cell Engineering, Celica Biomedical, Ljubljana, 1000, Slovenia
| | - Maria Waldhoer
- InterAx Biotech AG, PARK innovAARE, Villigen, 5234, Switzerland
| | - Peter Kolb
- Department of Pharmaceutical Chemistry, Philipps-University Marburg, Marburg, 35039, Germany
| |
Collapse
|
27
|
Mallo-Abreu A, Majellaro M, Jespers W, Azuaje J, Caamaño O, García-Mera X, Brea JM, Loza MI, Gutiérrez-de-Terán H, Sotelo E. Trifluorinated Pyrimidine-Based A2B Antagonists: Optimization and Evidence of Stereospecific Recognition. J Med Chem 2019; 62:9315-9330. [DOI: 10.1021/acs.jmedchem.9b01340] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
| | | | - Willem Jespers
- Department of Cell and Molecular Biology, Uppsala University, Uppsala SE-75124, Sweden
| | | | | | | | - José M. Brea
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - María I. Loza
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | | | | |
Collapse
|
28
|
da Silva-Candal A, Pérez-Díaz A, Santamaría M, Correa-Paz C, Rodríguez-Yáñez M, Ardá A, Pérez-Mato M, Iglesias-Rey R, Brea J, Azuaje J, Sotelo E, Sobrino T, Loza MI, Castillo J, Campos F. Clinical validation of blood/brain glutamate grabbing in acute ischemic stroke. Ann Neurol 2018; 84:260-273. [DOI: 10.1002/ana.25286] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2018] [Revised: 06/29/2018] [Accepted: 06/29/2018] [Indexed: 01/28/2023]
Affiliation(s)
- Andrés da Silva-Candal
- Clinical Neurosciences Research Laboratory, Department of Neurology; Clinical University Hospital, Health Research Institute of Santiago de Compostela; Santiago de Compostela Spain
| | - Amparo Pérez-Díaz
- Drug Screening Platform/Biofarma Research Group, Molecular Medicine and Chronic Diseases Research Center; University of Santiago de Compostela; Santiago de Compostela Spain
| | - María Santamaría
- Clinical Neurosciences Research Laboratory, Department of Neurology; Clinical University Hospital, Health Research Institute of Santiago de Compostela; Santiago de Compostela Spain
| | - Clara Correa-Paz
- Clinical Neurosciences Research Laboratory, Department of Neurology; Clinical University Hospital, Health Research Institute of Santiago de Compostela; Santiago de Compostela Spain
| | - Manuel Rodríguez-Yáñez
- Clinical Neurosciences Research Laboratory, Department of Neurology; Clinical University Hospital, Health Research Institute of Santiago de Compostela; Santiago de Compostela Spain
| | - Ana Ardá
- Molecular Recognition and Host-Pathogen Interactions Unit, CIC bioGUNE; Derio Spain
| | - María Pérez-Mato
- Clinical Neurosciences Research Laboratory, Department of Neurology; Clinical University Hospital, Health Research Institute of Santiago de Compostela; Santiago de Compostela Spain
| | - Ramón Iglesias-Rey
- Clinical Neurosciences Research Laboratory, Department of Neurology; Clinical University Hospital, Health Research Institute of Santiago de Compostela; Santiago de Compostela Spain
| | - José Brea
- Drug Screening Platform/Biofarma Research Group, Molecular Medicine and Chronic Diseases Research Center; University of Santiago de Compostela; Santiago de Compostela Spain
| | - Jhonny Azuaje
- Center for Research in Biological Chemistry and Molecular Materials (CIQUS); University of Santiago de Compostela; Santiago de Compostela Spain
| | - Eddy Sotelo
- Center for Research in Biological Chemistry and Molecular Materials (CIQUS); University of Santiago de Compostela; Santiago de Compostela Spain
| | - Tomás Sobrino
- Clinical Neurosciences Research Laboratory, Department of Neurology; Clinical University Hospital, Health Research Institute of Santiago de Compostela; Santiago de Compostela Spain
| | - M. Isabel Loza
- Drug Screening Platform/Biofarma Research Group, Molecular Medicine and Chronic Diseases Research Center; University of Santiago de Compostela; Santiago de Compostela Spain
| | - José Castillo
- Clinical Neurosciences Research Laboratory, Department of Neurology; Clinical University Hospital, Health Research Institute of Santiago de Compostela; Santiago de Compostela Spain
| | - Francisco Campos
- Clinical Neurosciences Research Laboratory, Department of Neurology; Clinical University Hospital, Health Research Institute of Santiago de Compostela; Santiago de Compostela Spain
| |
Collapse
|
29
|
Kalash L, Val C, Azuaje J, Loza MI, Svensson F, Zoufir A, Mervin L, Ladds G, Brea J, Glen R, Sotelo E, Bender A. Computer-aided design of multi-target ligands at A 1R, A 2AR and PDE10A, key proteins in neurodegenerative diseases. J Cheminform 2017; 9:67. [PMID: 29290010 PMCID: PMC5748027 DOI: 10.1186/s13321-017-0249-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2017] [Accepted: 12/01/2017] [Indexed: 01/30/2023] Open
Abstract
Compounds designed to display polypharmacology may have utility in treating complex diseases, where activity at multiple targets is required to produce a clinical effect. In particular, suitable compounds may be useful in treating neurodegenerative diseases by promoting neuronal survival in a synergistic manner via their multi-target activity at the adenosine A1 and A2A receptors (A1R and A2AR) and phosphodiesterase 10A (PDE10A), which modulate intracellular cAMP levels. Hence, in this work we describe a computational method for the design of synthetically feasible ligands that bind to A1 and A2A receptors and inhibit phosphodiesterase 10A (PDE10A), involving a retrosynthetic approach employing in silico target prediction and docking, which may be generally applicable to multi-target compound design at several target classes. This approach has identified 2-aminopyridine-3-carbonitriles as the first multi-target ligands at A1R, A2AR and PDE10A, by showing agreement between the ligand and structure based predictions at these targets. The series were synthesized via an efficient one-pot scheme and validated pharmacologically as A1R/A2AR-PDE10A ligands, with IC50 values of 2.4-10.0 μM at PDE10A and Ki values of 34-294 nM at A1R and/or A2AR. Furthermore, selectivity profiling of the synthesized 2-amino-pyridin-3-carbonitriles against other subtypes of both protein families showed that the multi-target ligand 8 exhibited a minimum of twofold selectivity over all tested off-targets. In addition, both compounds 8 and 16 exhibited the desired multi-target profile, which could be considered for further functional efficacy assessment, analog modification for the improvement of selectivity towards A1R, A2AR and PDE10A collectively, and evaluation of their potential synergy in modulating cAMP levels.
Collapse
Affiliation(s)
- Leen Kalash
- Department of Chemistry, Centre for Molecular Informatics, University of Cambridge, Lensfield Road, Cambridge, CB21EW UK
| | - Cristina Val
- Center for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
- Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Jhonny Azuaje
- Center for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - María I. Loza
- Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Fredrik Svensson
- Department of Chemistry, Centre for Molecular Informatics, University of Cambridge, Lensfield Road, Cambridge, CB21EW UK
- IOTA Pharmaceuticals Ltd, St Johns Innovation Centre, Cowley Road, Cambridge, CB40WS UK
| | - Azedine Zoufir
- Department of Chemistry, Centre for Molecular Informatics, University of Cambridge, Lensfield Road, Cambridge, CB21EW UK
| | - Lewis Mervin
- Department of Chemistry, Centre for Molecular Informatics, University of Cambridge, Lensfield Road, Cambridge, CB21EW UK
- Discovery Sciences, AstraZeneca R&D, Cambridge Science Park, Cambridge, UK
| | - Graham Ladds
- Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB21QJ UK
| | - José Brea
- Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Robert Glen
- Department of Chemistry, Centre for Molecular Informatics, University of Cambridge, Lensfield Road, Cambridge, CB21EW UK
- Division of Computational and Systems Medicine, Department of Surgery and Cancer, Imperial College London, London, UK
| | - Eddy Sotelo
- Center for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Andreas Bender
- Department of Chemistry, Centre for Molecular Informatics, University of Cambridge, Lensfield Road, Cambridge, CB21EW UK
| |
Collapse
|
30
|
Díaz-Marta AS, Tubío CR, Carbajales C, Fernández C, Escalante L, Sotelo E, Guitián F, Barrio VL, Gil A, Coelho A. Three-Dimensional Printing in Catalysis: Combining 3D Heterogeneous Copper and Palladium Catalysts for Multicatalytic Multicomponent Reactions. ACS Catal 2017. [DOI: 10.1021/acscatal.7b02592] [Citation(s) in RCA: 67] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Antonio S. Díaz-Marta
- Centro
Singular de Investigación en Química Biolóxica
e Materiáis Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - Carmen R. Tubío
- Instituto
de Cerámica, Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - Carlos Carbajales
- Centro
Singular de Investigación en Química Biolóxica
e Materiáis Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - Carmen Fernández
- Centro
Singular de Investigación en Química Biolóxica
e Materiáis Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - Luz Escalante
- Centro
Singular de Investigación en Química Biolóxica
e Materiáis Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - Eddy Sotelo
- Centro
Singular de Investigación en Química Biolóxica
e Materiáis Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain
- Departamento
de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, 15782, Santiago
de Compostela, Spain
| | - Francisco Guitián
- Instituto
de Cerámica, Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - V. Laura Barrio
- Escuela
de Ingeniería, Universidad del País Vasco, Alameda Urquijo
s/n, 48013, Bilbao, Spain
| | - Alvaro Gil
- Instituto
de Cerámica, Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - Alberto Coelho
- Centro
Singular de Investigación en Química Biolóxica
e Materiáis Moleculares (CIQUS), Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain
- Departamento
de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, 15782, Santiago
de Compostela, Spain
| |
Collapse
|
31
|
Azuaje J, López P, Iglesias A, de la Fuente RA, Pérez-Rubio JM, García D, Stępniewski TM, García-Mera X, Brea JM, Selent J, Pérez D, Castro M, Loza MI, Sotelo E. Development of Fluorescent Probes that Target Serotonin 5-HT 2B Receptors. Sci Rep 2017; 7:10765. [PMID: 28883627 PMCID: PMC5589878 DOI: 10.1038/s41598-017-11370-2] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2017] [Accepted: 08/23/2017] [Indexed: 01/07/2023] Open
Abstract
Some 5-HT2B fluorescent probes were obtained by tagging 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine (DOI) with a subset of fluorescent amines. Some of the resulting fluorescent ligands showed excellent affinity and selectivity profiles at the 5-HT2B receptors (e.g. 12b), while retain the agonistic functional behaviour of the model ligand (DOI). The study highlighted the most salient features of the structure-activity relationship in this series and these were substantiated by a molecular modelling study based on a receptor-driven docking model constructed on the basis of the crystal structure of the human 5-HT2B receptor. One of the fluorescent ligands developed in this work, compound 12i, specifically labelled CHO-K1 cells expressing 5-HT2B receptors and not parental CHO-K1 cells in a concentration-dependent manner. 12i enables imaging and quantification of specific 5-HT2B receptor labelling in live cells by automated fluorescence microscopy as well as quantification by measurements of fluorescence intensity using a fluorescence plate reader.
Collapse
Affiliation(s)
- Jhonny Azuaje
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
- Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
- Instituto de Farmacia Industrial (IFI), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
| | - Paula López
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
- Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
- Instituto de Farmacia Industrial (IFI), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
| | - Alba Iglesias
- Instituto de Farmacia Industrial (IFI), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
- Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas (CIMUS), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
| | - Rocío A de la Fuente
- Instituto de Farmacia Industrial (IFI), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
- Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas (CIMUS), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
| | - José M Pérez-Rubio
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
- Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
| | - Diego García
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
| | - Tomasz Maciej Stępniewski
- PharmacoInformatics Group, Research Program on Biomedical Informatics (GRIB) PRBB, Barcelona, 08003, Spain
| | - Xerardo García-Mera
- Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
- Instituto de Farmacia Industrial (IFI), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
| | - José M Brea
- Instituto de Farmacia Industrial (IFI), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
- Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas (CIMUS), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
| | - Jana Selent
- PharmacoInformatics Group, Research Program on Biomedical Informatics (GRIB) PRBB, Barcelona, 08003, Spain
- Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, 02-093, Warsaw, Poland
| | - Dolores Pérez
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
- Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
| | - Marián Castro
- Instituto de Farmacia Industrial (IFI), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
- Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas (CIMUS), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
| | - María I Loza
- Instituto de Farmacia Industrial (IFI), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
- Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas (CIMUS), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain
| | - Eddy Sotelo
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain.
- Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain.
- Instituto de Farmacia Industrial (IFI), Universidade de Santiago de Compostela, E-15782, Santiago de Compostela, Spain.
| |
Collapse
|
32
|
Azuaje J, Jespers W, Yaziji V, Mallo A, Majellaro M, Caamaño O, Loza MI, Cadavid MI, Brea J, Åqvist J, Sotelo E, Gutiérrez-de-Terán H. Effect of Nitrogen Atom Substitution in A3 Adenosine Receptor Binding: N-(4,6-Diarylpyridin-2-yl)acetamides as Potent and Selective Antagonists. J Med Chem 2017; 60:7502-7511. [DOI: 10.1021/acs.jmedchem.7b00860] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
| | - Willem Jespers
- Department
of Cell and Molecular Biology, Uppsala University, Uppsala SE-75124, Sweden
| | | | | | | | | | | | | | | | - Johan Åqvist
- Department
of Cell and Molecular Biology, Uppsala University, Uppsala SE-75124, Sweden
| | | | | |
Collapse
|
33
|
Abstract
Nearly 90 years ago, Drury and Szent-Györgyi revealed that adenosine produced profound hypotension and bradycardia, and it affected kidney function in mammals [1]. [...].
Collapse
Affiliation(s)
- Francisco Ciruela
- Unitat de Farmacologia, Departament Patologia i Terapèutica Experimental, Facultat de Medicina, IDIBELL-Universitat de Barcelona, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
- Institut de Neurociències, Universitat de Barcelona, 08035 Barcelona, Spain.
| | - Eddy Sotelo
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
- Departamento de Química Orgánica, Facultad de Farmacia, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
| |
Collapse
|
34
|
Maatougui AE, Yáñez M, Crespo A, Fraiz N, Coelho A, Raviña E, Laguna R, Cano E, Loza MI, Brea J, Gutiérrez de Terán H, Sotelo E. 3-Oxopyridazin-5-yl-Chalcone Hybrids: Potent Antiplatelet Agents That Prevent Glycoprotein IIb/IIIa Activation. ChemistrySelect 2017. [DOI: 10.1002/slct.201700243] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Abdelaziz El Maatougui
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS); Universidade de Santiago de Compostela; 15782 Santiago de Compostela Spain
| | - Matilde Yáñez
- Departamento de Farmacología, Facultade de Farmacia; Universidade de Santiago de Compostela; 15782 Santiago de Compostela Spain
| | - Abel Crespo
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS); Universidade de Santiago de Compostela; 15782 Santiago de Compostela Spain
| | - Nuria Fraiz
- Departamento de Farmacología, Facultade de Farmacia; Universidade de Santiago de Compostela; 15782 Santiago de Compostela Spain
| | - Alberto Coelho
- Departamento de Química Orgánica, Facultade de Farmacia; Universidade de Santiago de Compostela; 15782 Santiago de Compostela Spain
| | - Enrique Raviña
- Departamento de Química Orgánica, Facultade de Farmacia; Universidade de Santiago de Compostela; 15782 Santiago de Compostela Spain
| | - Reyes Laguna
- Departamento de Farmacología, Facultade de Farmacia; Universidade de Santiago de Compostela; 15782 Santiago de Compostela Spain
| | - Ernesto Cano
- Departamento de Farmacología, Facultade de Farmacia; Universidade de Santiago de Compostela; 15782 Santiago de Compostela Spain
| | - María I. Loza
- Departamento de Farmacología, Facultade de Farmacia; Universidade de Santiago de Compostela; 15782 Santiago de Compostela Spain
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS).; Universidade de Santiago de Compostela; 15782 Santiago de Compostela Spain
| | - José Brea
- Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS).; Universidade de Santiago de Compostela; 15782 Santiago de Compostela Spain
| | | | - Eddy Sotelo
- Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS); Universidade de Santiago de Compostela; 15782 Santiago de Compostela Spain
- Departamento de Química Orgánica, Facultade de Farmacia; Universidade de Santiago de Compostela; 15782 Santiago de Compostela Spain
| |
Collapse
|
35
|
Carbajales C, Azuaje J, Oliveira A, Loza MI, Brea J, Cadavid MI, Masaguer CF, García-Mera X, Gutiérrez-de-Terán H, Sotelo E. Enantiospecific Recognition at the A2B Adenosine Receptor by Alkyl 2-Cyanoimino-4-substituted-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylates. J Med Chem 2017; 60:3372-3382. [DOI: 10.1021/acs.jmedchem.7b00138] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
| | | | - Ana Oliveira
- Department
of Cell and Molecular Biology, Uppsala University, Uppsala SE-75124, Sweden
| | - María I. Loza
- Drug
Screening Platform/Biofarma Research Group, Centro Singular de Investigación
en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela, 15782 Santiago
de Compostela, Spain
| | - José Brea
- Drug
Screening Platform/Biofarma Research Group, Centro Singular de Investigación
en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela, 15782 Santiago
de Compostela, Spain
| | - María I. Cadavid
- Drug
Screening Platform/Biofarma Research Group, Centro Singular de Investigación
en Medicina Molecular y Enfermedades Crónicas (CIMUS), Universidade de Santiago de Compostela, 15782 Santiago
de Compostela, Spain
| | | | | | | | | |
Collapse
|
36
|
Carbajales C, Sawada JI, Marzaro G, Sotelo E, Escalante L, Sánchez-Díaz Marta A, García-Mera X, Asai A, Coelho A. Multicomponent Assembly of the Kinesin Spindle Protein Inhibitor CPUYJ039 and Analogues as Antimitotic Agents. ACS Comb Sci 2017; 19:153-160. [PMID: 28135059 DOI: 10.1021/acscombsci.6b00166] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The potent kinesin spindle protein inhibitor CPUYJ039 and a set of analogues were prepared by a target-oriented approach based on a Ugi reaction that uses 2-nitrophenyl isocyanides as key building blocks. The herein documented strategy provides straightforward and atom economical access to potent benzimidazole-based antimitotic agents by exploring the versatility and exploratory power of the Ugi reaction. The results of docking studies and biological activity evaluations of the benzimidazole compounds are also reported.
Collapse
Affiliation(s)
- Carlos Carbajales
- Center
for Research in Biological Chemistry and Molecular Materials, University of Santiago de Compostela, Jenaro de la Fuente s/n, Campus
Vida, Santiago de Compostela 15782, Spain
| | - Jun-ichi Sawada
- Graduate
School of Pharmaceutical Sciences, University of Shizuoka, Suruga-ku, Shizuoka 422-8526, Japan
| | - Giovanni Marzaro
- Department
of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy
| | - Eddy Sotelo
- Center
for Research in Biological Chemistry and Molecular Materials, University of Santiago de Compostela, Jenaro de la Fuente s/n, Campus
Vida, Santiago de Compostela 15782, Spain
- Department
of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Avenida das Ciencias, s/n, Campus sur, Santiago de Compostela 15782, Spain
| | - Luz Escalante
- Center
for Research in Biological Chemistry and Molecular Materials, University of Santiago de Compostela, Jenaro de la Fuente s/n, Campus
Vida, Santiago de Compostela 15782, Spain
| | - Antonio Sánchez-Díaz Marta
- Center
for Research in Biological Chemistry and Molecular Materials, University of Santiago de Compostela, Jenaro de la Fuente s/n, Campus
Vida, Santiago de Compostela 15782, Spain
| | - Xerardo García-Mera
- Department
of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Avenida das Ciencias, s/n, Campus sur, Santiago de Compostela 15782, Spain
| | - Akira Asai
- Graduate
School of Pharmaceutical Sciences, University of Shizuoka, Suruga-ku, Shizuoka 422-8526, Japan
| | - Alberto Coelho
- Center
for Research in Biological Chemistry and Molecular Materials, University of Santiago de Compostela, Jenaro de la Fuente s/n, Campus
Vida, Santiago de Compostela 15782, Spain
- Department
of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Avenida das Ciencias, s/n, Campus sur, Santiago de Compostela 15782, Spain
| |
Collapse
|
37
|
Gutiérrez-de-Terán H, Sallander J, Sotelo E. Structure-Based Rational Design of Adenosine Receptor Ligands. Curr Top Med Chem 2017; 17:40-58. [PMID: 27448653 DOI: 10.2174/1568026616666160719164207] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2016] [Revised: 01/27/2016] [Accepted: 02/25/2016] [Indexed: 11/22/2022]
Abstract
The family of adenosine receptors (ARs) is focus of several medicinal chemistry programs aimed to find new potent and selective drugs. Each receptor subtype has been proposed as a relevant drug target in the treatment of, e.g., cardiovascular or inflammatory diseases, asthma or Parkinson's disease. Until recently, most of these efforts have been dominated by ligand-based or empirical approaches. However, the latest advances in G protein-coupled receptor (GPCR) crystallography allowed for a thorough structural characterization of the A2AAR subtype, which has been crystalized with a number of agonists and antagonists. Consequently, the ligand discovery of AR ligands has been enriched with a number of structure-based approaches. These include the generation of higher-confident homology models for the remaining AR subtypes, virtual screening identification of novel chemotypes, structure-based lead-optimization programs, rationalization of selectivity profiles, or the structural characterization of novel binding sites that enable the design of novel allosteric modulators. Computational methodologies have importantly contributed to the success of these structure-based approaches, and the recent advances in the field are also analyzed in this review. We conclude that the design of adenosine receptor ligands has improved dramatically with the consideration of structure- based approaches, which is paving the way to a better understanding of the biology and pharmacological modulation of this relevant family of receptors.
Collapse
Affiliation(s)
- Hugo Gutiérrez-de-Terán
- Department of Cell and Molecular Biology, Uppsala University, Biomedical Center, Box 596, SE-751 24 Uppsala, Sweden.
| | | | | |
Collapse
|
38
|
Raviña-Eirin E, Azuaje J, Sotelo E, Gomez-Amoza JL, Martinez-Pacheco R. Drug structural features affect drug delivery from hyperbranched polyesteramide hot melt extrudates. Eur J Pharm Biopharm 2016; 102:1-8. [PMID: 26912462 DOI: 10.1016/j.ejpb.2016.02.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2015] [Revised: 01/08/2016] [Accepted: 02/14/2016] [Indexed: 11/27/2022]
Abstract
The aim of this study was firstly to evaluate the utility of Hybrane S1200 as a hot melt extrusion (HME) carrier to prepare instant-release multiparticulate systems for very poorly-soluble drugs such as ketoconazole or nifedipine. Hybrane S1200 allows an easy extrusion of its drug mixtures at a relatively low temperature, not higher than 90°C, and with no need of any additional aid. Extrudates containing 10% of nifedipine or ketoconazole form monophasic systems. Nifedipine extrudate shows no drug release in drug dissolution rate tests while ketoconazole extrudate release reaches only 60% of drug content. Additionally, a turbidity in the dissolution medium due to the formation of a kind of polymer vesicles (ranging 3-0.2μm in size) is observed. These facts could suggest a chemical interaction between the polymer and both drugs, triggered by the HME process. Both nifedipine and ketoconazole share characteristic acid-base profiles that could facilitate a degradation processes within the polymer, thus modifying Hybrane's water-solubility and polar nature. Such modified polymer structure, when in aqueous medium, forms the aforementioned stable vesicles that may encapsulate the drugs, thus making its delivery difficult or even preventing it.
Collapse
Affiliation(s)
- Elena Raviña-Eirin
- Department of Pharmacy and Pharmaceutical Technology and Institute of Industrial Pharmacy, Faculty of Pharmacy, University of Santiago de Compostela, 15782, Spain
| | - Jhonny Azuaje
- Center for Research in Biological Chemistry and Molecular Materials (CIQUS) and Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782, Spain
| | - Eddy Sotelo
- Center for Research in Biological Chemistry and Molecular Materials (CIQUS) and Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782, Spain
| | - Jose Luis Gomez-Amoza
- Department of Pharmacy and Pharmaceutical Technology and Institute of Industrial Pharmacy, Faculty of Pharmacy, University of Santiago de Compostela, 15782, Spain
| | - Ramon Martinez-Pacheco
- Department of Pharmacy and Pharmaceutical Technology and Institute of Industrial Pharmacy, Faculty of Pharmacy, University of Santiago de Compostela, 15782, Spain.
| |
Collapse
|
39
|
El Maatougui A, Azuaje J, González-Gómez M, Miguez G, Crespo A, Carbajales C, Escalante L, García-Mera X, Gutiérrez-de-Terán H, Sotelo E. Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes. J Med Chem 2016; 59:1967-83. [DOI: 10.1021/acs.jmedchem.5b01586] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
40
|
|
41
|
Azuaje J, Pérez-Rubio JM, Yaziji V, El Maatougui A, González-Gomez JC, Sánchez-Pedregal VM, Navarro-Vázquez A, Masaguer CF, Teijeira M, Sotelo E. Integrated Ugi-Based Assembly of Functionally, Skeletally, and Stereochemically Diverse 1,4-Benzodiazepin-2-ones. J Org Chem 2015; 80:1533-49. [DOI: 10.1021/jo502382q] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Affiliation(s)
| | | | | | | | | | | | - Armando Navarro-Vázquez
- Departamento
de Quı́mica Orgánica, Facultad de Quı́mica, Universidad de Vigo, E-36310 Vigo, Spain
| | | | - Marta Teijeira
- Departamento
de Quı́mica Orgánica, Facultad de Quı́mica, Universidad de Vigo, E-36310 Vigo, Spain
| | | |
Collapse
|
42
|
Abstract
An expedient and concise Ugi-based unified approach for the rapid assembly of quinoxaline frameworks has been developed. This convergent and versatile method uses readily available commercial reagents, does not require advanced intermediates, and exhibits excellent bond-forming efficiency, thus exemplifying the operationally simple synthesis of quinoxaline libraries.
Collapse
Affiliation(s)
- Jhonny Azuaje
- Center for Research in Biological
Chemistry and Molecular Materials
(CIQUS), ‡Institute of Industrial Pharmacy, and §Department of Organic Chemistry,
Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Abdelaziz El Maatougui
- Center for Research in Biological
Chemistry and Molecular Materials
(CIQUS), ‡Institute of Industrial Pharmacy, and §Department of Organic Chemistry,
Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Xerardo García-Mera
- Center for Research in Biological
Chemistry and Molecular Materials
(CIQUS), ‡Institute of Industrial Pharmacy, and §Department of Organic Chemistry,
Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Eddy Sotelo
- Center for Research in Biological
Chemistry and Molecular Materials
(CIQUS), ‡Institute of Industrial Pharmacy, and §Department of Organic Chemistry,
Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| |
Collapse
|
43
|
Carbajales C, Prado MÁ, Gutiérrez-de-Terán H, Cores Á, Azuaje J, Novio S, Nuñez MJ, Fernández-García B, Sotelo E, García-Mera X, Sánchez-Lazo P, Freire-Garabal M, Coelho A. Structure-Based Design of New KSP-Eg5 Inhibitors Assisted by a Targeted Multicomponent Reaction. Chembiochem 2014; 15:1471-80. [DOI: 10.1002/cbic.201402089] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2014] [Indexed: 11/06/2022]
|
44
|
Crespo A, El Maatougui A, Biagini P, Azuaje J, Coelho A, Brea J, Loza M, Cadavid MI, García-Mera X, Gutiérrez-de-Terán H, Sotelo E. Discovery of 3,4-Dihydropyrimidin-2(1H)-ones As a Novel Class of Potent and Selective A2B Adenosine Receptor Antagonists. ACS Med Chem Lett 2013; 4:1031-6. [PMID: 24900602 PMCID: PMC4027370 DOI: 10.1021/ml400185v] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2013] [Accepted: 10/03/2013] [Indexed: 01/18/2023] Open
Abstract
We describe the discovery and optimization of 3,4-dihydropyrimidin-2(1H)-ones as a novel family of (nonxanthine) A2B receptor antagonists that exhibit an unusually high selectivity profile. The Biginelli-based hit optimization process enabled a thoughtful exploration of the structure-activity and structure-selectivity relationships for this chemotype, enabling the identification of ligands that combine structural simplicity with excellent hA2B AdoR affinity and remarkable selectivity profiles.
Collapse
Affiliation(s)
- Abel Crespo
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Abdelaziz El Maatougui
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Pierfrancesco Biagini
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Jhonny Azuaje
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Alberto Coelho
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - José Brea
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - María
Isabel Loza
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - María Isabel Cadavid
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Xerardo García-Mera
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| | - Hugo Gutiérrez-de-Terán
- Department of Cell
and Molecular Biology, Uppsala University,
Biomedical Center, Uppsala SE-75124, Sweden
| | - Eddy Sotelo
- Center for Research in Biological Chemistry and Molecular
Materials (CIQUS), Institute of Industrial Pharmacy, Department of Organic Chemistry, Faculty of
Pharmacy, University of Santiago de Compostela, Santiago de Compostela 15782, Spain
| |
Collapse
|
45
|
Val C, Crespo A, Yaziji V, Coelho A, Azuaje J, El Maatougui A, Carbajales C, Sotelo E. Three-component assembly of structurally diverse 2-aminopyrimidine-5-carbonitriles. ACS Comb Sci 2013; 15:370-8. [PMID: 23697392 DOI: 10.1021/co4000503] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
An expedient route for the synthesis of libraries of diversely decorated 2-aminopyrimidine-5-carbonitriles is reported. This approach is based on a three-component reaction followed by spontaneous aromatization.
Collapse
Affiliation(s)
- Cristina Val
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS) and ‡Department of
Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela,
15782, Spain
| | - Abel Crespo
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS) and ‡Department of
Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela,
15782, Spain
| | - Vicente Yaziji
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS) and ‡Department of
Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela,
15782, Spain
| | - Alberto Coelho
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS) and ‡Department of
Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela,
15782, Spain
| | - Jhonny Azuaje
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS) and ‡Department of
Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela,
15782, Spain
| | - Abdelaziz El Maatougui
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS) and ‡Department of
Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela,
15782, Spain
| | - Carlos Carbajales
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS) and ‡Department of
Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela,
15782, Spain
| | - Eddy Sotelo
- Center
for Research in Biological Chemistry and Molecular Materials (CIQUS) and ‡Department of
Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela,
15782, Spain
| |
Collapse
|
46
|
Diz PM, Coelho A, El Maatougui A, Azuaje J, Caamaño O, Gil Á, Sotelo E. Copper-catalyzed Huisgen 1,3-dipolar cycloaddition under oxidative conditions: polymer-assisted assembly of 4-acyl-1-substituted-1,2,3-triazoles. J Org Chem 2013; 78:6540-9. [PMID: 23738944 DOI: 10.1021/jo400800j] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
We herein document the first example of a reliable copper-catalyzed Huisgen 1,3-dipolar cycloaddition under oxidative conditions. The combined use of two polymer-supported reagents (polystyrene-1,5,7-triazabicyclo[4,4,0]dec-5-ene/Cu and polystyrene-2-iodoxybenzamide) overcomes the thermodynamic instability of copper(I) species toward oxidation, enabling the reliable Cu-catalyzed Huisgen 1,3-dipolar cycloadditions in the presence of an oxidant agent. This polymer-assisted pathway, not feasible under conventional homogeneous conditions, provides a direct assembly of 4-acyl-1-substituted-1,2,3-triazoles, contributing to expand the reliability and scope of Cu(I)-catalyzed alkyne-azide cycloaddition.
Collapse
Affiliation(s)
- Paula M Diz
- Center for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | | | | | | | | | | | | |
Collapse
|
47
|
Azuaje J, El Maatougui A, Pérez-Rubio JM, Coelho A, Fernández F, Sotelo E. Multicomponent Assembly of Diverse Pyrazin-2(1H)-one Chemotypes. J Org Chem 2013; 78:4402-9. [DOI: 10.1021/jo4003163] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Jhonny Azuaje
- Center for Research in Biological Chemistry
and Molecular Materials (CIQUS)
- Department of Organic Chemistry, Faculty
of Pharmacy, University of Santiago de Compostela, Santiago de Compostela,
15782, Spain
| | - Abdelaziz El Maatougui
- Center for Research in Biological Chemistry
and Molecular Materials (CIQUS)
- Department of Organic Chemistry, Faculty
of Pharmacy, University of Santiago de Compostela, Santiago de Compostela,
15782, Spain
| | - José M. Pérez-Rubio
- Center for Research in Biological Chemistry
and Molecular Materials (CIQUS)
- Department of Organic Chemistry, Faculty
of Pharmacy, University of Santiago de Compostela, Santiago de Compostela,
15782, Spain
| | - Alberto Coelho
- Center for Research in Biological Chemistry
and Molecular Materials (CIQUS)
- Department of Organic Chemistry, Faculty
of Pharmacy, University of Santiago de Compostela, Santiago de Compostela,
15782, Spain
| | - Franco Fernández
- Department of Organic Chemistry, Faculty
of Pharmacy, University of Santiago de Compostela, Santiago de Compostela,
15782, Spain
| | - Eddy Sotelo
- Center for Research in Biological Chemistry
and Molecular Materials (CIQUS)
- Department of Organic Chemistry, Faculty
of Pharmacy, University of Santiago de Compostela, Santiago de Compostela,
15782, Spain
| |
Collapse
|
48
|
Yaziji V, Rodríguez D, Coelho A, García-Mera X, El Maatougui A, Brea J, Loza MI, Cadavid MI, Gutiérrez-de-Terán H, Sotelo E. Selective and potent adenosine A3 receptor antagonists by methoxyaryl substitution on the N-(2,6-diarylpyrimidin-4-yl)acetamide scaffold. Eur J Med Chem 2012; 59:235-42. [PMID: 23231967 DOI: 10.1016/j.ejmech.2012.11.010] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2012] [Revised: 11/06/2012] [Accepted: 11/08/2012] [Indexed: 11/18/2022]
Abstract
The influence of diverse methoxyphenyl substitution patterns on the N-(2,6-diarylpyrimidin-4-yl)acetamide scaffold is herein explored in order to modulate the A(3) adenosine receptor antagonistic profile. As a result, novel ligands exhibiting excellent potency (K(i) on A(3) AR < 20 nM) and selectivity profiles (above 100-fold within the adenosine receptors family) are reported. Moreover, our joint theoretical and experimental approach allows the identification of novel pharmacophoric elements conferring A(3)AR selectivity, first established by a robust computational model and thereafter characterizing the most salient features of the structure-activity and structure-selectivity relationships in this series.
Collapse
Affiliation(s)
- Vicente Yaziji
- Combinatorial Chemistry Unit (COMBIOMED), Center for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Rivera FP, Sotelo E, Morales I, Menacho F, Medina AM, Evaristo R, Valencia R, Carbajal L, Ruiz J, Ochoa TJ. Short communication: Detection of Shiga toxin-producing Escherichia coli (STEC) in healthy cattle and pigs in Lima, Peru. J Dairy Sci 2012; 95:1166-9. [PMID: 22365200 DOI: 10.3168/jds.2011-4662] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2011] [Accepted: 11/13/2011] [Indexed: 12/18/2022]
Abstract
The aim of this study was to determine the prevalence of Shiga toxin-producing Escherichia coli (STEC) in cattle and pigs as a possible STEC reservoir in Lima, Peru. One hundred and fourteen cattle and 112 pigs from 10 and 4 farms, respectively, were studied. Five E. coli colonies per culture were studied by a multiplex real-time PCR to identify Shiga toxin-producing (stx1, stx2, eaeA), enterotoxigenic (lt, st), enteropathogenic (eaeA), enteroinvasive (ipaH), enteroaggregative (aggR), and diffusely adherent E. coli (daaD). Shiga toxin-producing E. coli were isolated from 16 cattle (14%) but none from pigs. stx1 was found in all bovine isolates, 11 of which also carried eaeA genes (69%); only 1 sample had both stx1 and stx2. Thirteen stx-positive strains were classified as Shiga-toxigenic (81%) using an enzymatic immunoassay, 2 STEC strains were from serogroup O157 (13%), and 7 were sorbitol negative (44%). Enteropathogenic E. coli were detected more frequently in cattle (18%, 20/114) than in pigs (5%, 6/112). To our knowledge, this is the first study on the prevalence of STEC in farms animals in Peru using molecular methods. Further studies are needed in a large number of farms to determine the relevance of these findings and its consequences for public health.
Collapse
Affiliation(s)
- F P Rivera
- Universidad Peruana Cayetano Heredia, Av. Honorio Delgado 430, San Martin de Porres, Lima 31, Peru
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
El Maatougui A, Azuaje J, Coelho A, Cano E, Yañez M, López C, Yaziji V, Carbajales C, Sotelo E. Discovery and preliminary SAR of 5-arylidene-2,2-dimethyl-1,3-dioxane- 4,6-diones as platelet aggregation inhibitors. Comb Chem High Throughput Screen 2012; 15:551-4. [PMID: 22272691 DOI: 10.2174/138620712801619122] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2011] [Revised: 01/18/2012] [Accepted: 02/10/2012] [Indexed: 11/22/2022]
Abstract
We herein document the discovery of 5-arylidene-2,2-dimethyl-1,3-dioxane-4,6-diones as a novel family of platelet aggregation inhibitors. The preliminary optimization study enabled us to establish the most salient features of the structure-activity relationships in this series as well as to identify novel derivatives that are upto 60 times more potent than the hit structure 1 and slightly superior to the reference drug Milrinone.
Collapse
Affiliation(s)
- Abdelaziz El Maatougui
- Center for Research in Chemical Biology and Molecular Materials, University of Santiago de Compostela, Santiago de Compostela, 15782, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|